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Chapter I
INTRODUCTION

Activation of plasminogen to plasmin by urokinase
plasminogen activator may play an essential role in tumor
cell invasion and metastasis.

Plasmin is capable of

digesting the extracellular matrix and basement membrane.
It exerts its proteolytic action either directly by
degrading glycoproteins, such as laminin, fibronectin and
proteoglycans or indirectly by activating procollagenases
to collagenases.

Collagenases which degrade collagen, a

major structural protein of basement membrane, are
believed to contribute to the ability of a tumor cell to
metastasize.

Therefore it has been suggested that

urokinase plasminogen activator might be the essential
proteolytic enzyme to initiate the cascade of protease
activation that results in tumor cell invasion and
metastasis.
The goal of this dissertation was to study the
role of urokinase plasminogen activator in the metastatic

1
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process by a direct approach at the gene level.

This

study was carried out by increasing the production of
urokinase activity or inhibiting endogenous urokinase
production by means of the urokinase gene modification in
tumor cells and testing the metastatic potential of the
modified cells.
The results of this study may address the role of
the secreted form of urokinase in the later steps of the
metastatic process as well as in the full metastatic
process.

Chapter II
REVIEW OF THE LITERATURE
TUJ:Dor Cell Metastasis
Tumor cell metastasis is a transfer of malignant
tumor cells from the primary site of tumor formation to
distant organs, and is the major cause of cancer deaths.
The metastasis of tumor cells is a complex process which
involves multiple steps.
At the first step of metastasis, primary tumor cells
invade through the extracellular matrix and basement
membrane, spread into adjacent normal tissue, intravasate
through the capillary endothelial walls, and are
eventually released into the circulation.

Few tumor cells

survive the transit through the circulation.

Those tumor

cells that do survive arrest in the capillary beds of
distant organs and extravasate from the capillaries
through the basement membrane and extracellular matrix
into the surrounding normal tissue.

At the final step of

metastasis, the extravasated tumor cells grow and give

4

rise to secondary tumor deposits.
During the intravasation and extravasation steps,
tumor cells must invade a variety of extracellular
matrices and basement membranes in order to enter the
underlying interstitial stroma.

The extracellular matrix

is composed of a dense lattice of interstitial collagens
and elastin fibers embedded within a ground substance
consisting of fibronectin, other glycoproteins, and
proteoglycans.

The basement membrane is composed of type

IV collagen, laminin, other specific glycoproteins, and
heparan sulfate proteoglycans.
A three-step theory has been proposed by Liotta et
al. (1986) to explain the sequence of tumor cell invasion
to the extracellular matrix.

The first step is tumor cell

attachment to the matrix by cell surf ace receptors that
specifically bind components of the matrix, such as
laminin.

Laminin forms a bridge between the cell surface

laminin receptor and type IV collagen in the basement
membrane.

The second step of tumor cell invasion is the

local degradation of the matrix by proteolytic enzymes.
These are produced by tumor cells or host cells that have
been induced by tumor cells.

The third step is the tumor

cell locomotion into the region of matrix modified by the
proteolytic enzymes.

Thus the degradation of the above

5

tissue barrier by proteolytic enzymes is a part of the key
step of tumor cell invasion and, in turn, metastasis.

proteases Involved in Tumor Cell Invasion
Due to the complexity of the tissue barriers that
tumor cells must cross in the invasion process, the
degradation of the matrix may require several proteolytic
enzymes.

The proteolytic enzymes, which have been

implicated in this step are collagenases, particularly
type IV, endoglycosidases, cathepsin B-like thiol
proteinases, and plasminogen activators (Nicolson, 1982).
A cathepsin B-like proteinase can degrade several
components of the extracellular matrix such as denatured
collagen, fibronectin and proteoglycan (Sloane and Honn,
1984).

In addition, it has been suggested that cathepsin

B-like proteinase might have the potential to activate
latent type IV collagenase (Sloane et al., 1986).
Increased amounts of cathepsin B-like thiol proteinase
have been found in solid tumors (Poole et al., 1980;
Recklies et al., 1980; Rinderknecht and Renner, 1980; Ryan
et al., 1985), transformed cell (Myra-y-Loopez et al.,
1985), and tumor cells in culture (Sloan et al., 1981;
Sloane et al., 1982; Ryan et al., 1984).

However, there

\
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are contradictory results which do not find any
correlation between cathepsin B-like activity and
metastatic potential (McLaughlin et al., 1983).

Others

have reported that cathepsin B-like activity is negatively
correlated with transformation (Dolbeare et al., 1980;
Morgan et al., 1981).

Inhibitors of cathepsin B placed in

high steady-state concentrations within an animal model
for metastasis failed to show any inhibition of metastasis
(Ostrawski et al., 1986).
Endoglycosidases cleave heparan sulfate from matrix
proteoglycans.

Heparan sulfate interacts with matrix

macromolecules, such as collagens and fibronectin, and
plasma membrane attachment sites.

Therefore,

endoglycosidases have also been shown to be involved in
tumor invasion and metastasis (reviewed by Goldfarb and
Liotta, 1986).
Interstitial collagenases hydrolyze collagen types
I, II, and III of the extracellular matrix.

Several

investigators reported a positive correlation between
tumor cell secretion of interstitial collagenase by mouse
primary tumor cells and lung metastasis (Tarin et al.,
1982).

Another study showed the invasion of a chick

chorioallantoic membrane by human choriocarcinoma cell
lines correlated well with the production of collagenase

7

but did not correlate with secretion of plasminogen
activator or cathepsin B (Sekiya et al., 1985).
The major structural protein of basement membrane,
type IV collagen, is not degraded by the interstitial
collagenase, but by type IV collagenase (Salo et al.,
1982).

Type IV collagenase is secreted in a latent form

and shown to be activated by plasmin in vitro (Werb et
al., 1977; Paranjpe .§..t al., 1980; Gross et al., 1982; He
et al., 1989).

Enhanced levels of type IV collagenase has

been shown in malignant tumor cells (Liotta et al., 1986;
Goldfarb et al., 1986).

Positive correlation between type

IV collagenase activity and the pulmonary metastatic
potential has been demonstrated in Bl6 melanoma cell lines
(Liotta et al., 1980) and breast cancer cell lines
(Nakajima et al., 1986).
Plasminogen activator (PA) is a serine protease
which converts the inactive proenzyme plasminogen to
plasmin.

The plasminogen, is ubiquitous in the blood and

tissue spaces.

Plasmin can degrade many components of the

extracellular matrix in vitro such as proteoglycans
(Mochan and Keler, 1984), fibronectin (Liotta et al.,
1981; Kramer et al., 1982), and laminin (Liotta et al.,
1981; Boyd et al., 1989).

Plasmin has also been shown to

activate procollagenase to collagenase in vitro, including
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type IV collagenase, which degrades type IV collagen (Werb
gt al., 1977; Paranjpe et al., 1980; Gross et al., 1982;

He et al. 1989).

Therefore, plasminogen activator, via

activation of plasminogen, may have a central role in
initiating cascade reactions that degrade the molecules
composing the barriers which tumor cells must cross during
metastasis.

The details of plasminogen activator activity

in tumor cell metastasis will be discussed separately.
Two distinct types of plasminogen activators are
known, tissue-type plasminogen activator and urokinase
type.
forms.

They are genetically and immunologically distinct
The two proteins have different amino acid

sequences, molecular weights, subunit structures and
catalytic parameters such as affinity to fibrin.

Tissue-

type plasminogen activator is released from the
endothelial cells of the blood vessels and urokinase-type
plasminogen activator is synthesized in kidney cells and
released from the renal tubules.

Immunological

characterization has shown that most tumor cells produce
urokinase-type plasminogen activator rather than tissuetype (reviewed by Dano et al., 1985).

There are some

exceptions where tissue-type plasminogen activator was
demonstrated in breast tumor cells induced by carcinogens,
in melanoma cells (Dano et al., 1985), and several other
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tumor cell lines (Quax et al., 1990).

In general though

tissue-type plasminogen activator appears to be involved
in fibrinolytic function of the cell, such as lysis of
fibrin clots, and urokinase-type activity is involved in
cell migration and tumor cell metastasis.
In this report, the term "plasminogen activator" is
used when unable to identify which type of activator is
being studied.

The term "urokinase" is used when the

basis of its origin is from the urokinase plasminogen
activator identified by the urokinase plasminogen
activator gene or evaluated by immunological assays.
Tissue-type plasminogen activator is referred to as
"tissue PA".

Biochemistry of Urokinase

The urokinase gene has been isolated and sequenced
from human (Heyneker et al., 1983; Riccio et al., 1985;
Nagai et al., 1985), mouse (Degen et al., 1987), pig
(Nagamine et al., 1985), and chicken (Leslie et al.,
1990).

Comparison of the human urokinase gene and the

porcine, murine, or chicken gene has shown an extensive
homology (72-79% nucleotide sequence identity) throughout
the introns and exons (Degen et al., 1987).

The four

10
urokinase genes are also similar in size: human, 6388 base
pairs: porcine, 5852 base pairs; murine, 6710 base pairs;
and chicken, 8158 base pairs (Degen et al., 1987).

The

human urokinase gene is located on the long arm of
chromosome 10 (Tripputi et al., 1985), while human tissue
PA is on chromosome 8 (Blasi et al., 1986).

The human

urokinase gene consists of 11 exons and 10 introns (Riccio
et al., 1985).

~

~

The mRNA of human urokinase is shown to be

2.5 Kb and the cDNA is composed of 1293 base pairs (Verde
et al., 1984).

Human urokinase is a glycoprotein (Holmes

et al., 1985; Ricco et al., 1985) while mouse urokinase
contains no N-glycosylation site (Belin et al., 1985).
Urokinase is synthesized as a single-chain
preprourokinase composed of 431 amino acids as shown by
its cDNA size and has a molecular weight of 54 Kd (Salerno
et al., 1984).

It contains a signal leader sequence of 20

amino acids which is removed during protein synthesis
(Pennica et gl., 1983).

Urokinase is secreted as an

inactive single-chain prourokinase zymogen of 411
residues.

However, some investigators reported that

prourokinase purified from certain cell lines demonstrated
catalytic activity (Stumpt et al., 1986; Ellis et al.,
1987).

The single-chain prourokinase is activated by a

proteolytic cleavage which removes one amino acid, lysine,
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at position 158.

Thus the activation generates a two-

chain urokinase molecule (A-chain and B-chain) held
together by one disulfide bond (Gunzler et al., 1982).
The activation is mediated by many compounds such as
plasmin (Dano et al., 1985), plasma kallikrein (Ichinose
et al., 1986), factor XIIa (Ichinose et al., 1986),

~

~

trypsin (Eaton et al., 1984), and thrombin (Eaton et al.,
1984).

Plasmin appears to be the most efficient activator

(Eaton et al., 1984; Ichinose et al., 1986).

At certain

concentrations, thrombin has been found to inactivate
prourokinase by cleaving arg-156 and phe-157 (van
Hinsbergh et al., 1987).

The active urokinase can be

further cleaved by plasmin to form a still active 33 Kd
molecule (Stump et al., 1986).

Whether the 33 Kd

urokinase has specific function is not known.
Urokinase consists of five distinctive domains,
known as the signal domain, growth factor domain, kringle
domain, connecting domain, and catalytic domain (Verde et
al., 1984).

The growth domain is homologous to epidermal

growth factor, alpha transforming growth factor,
coagulation factors IX and X, and prothrombin (Anson et
al., 1984; Fernlund et al., 1982).

The homology to growth

factors might suggest a growth promoting activity of
urokinase in certain cell lines (Kirchheimer et al.,
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l987).

The kringle domain is also present in other

zymogens, such as prothrombin (Magnusson et al., 1976) and
plasminogen (Sottrup-Jensen et al., 1978).

The catalytic

domain carries the typical active site of the serine
proteases.

Comparison of the amino acid sequence of

tissue PA and urokinase shows that two domains of the
tissue PA are missing in urokinase.

The first missing

domain is the finger-like domain which may be responsible
for the high affinity of tissue PA for fibrin (Banyai et
al., 1983) and explains the greater fibrinolytic effect of
tissue PA than of urokinase.

The second missing domain in

urokinase is the second kringle domain of tissue PA.
The production of urokinase is affected by several
compounds such as hormones, growth factors, cAMP, and
tumor promoters.

It was shown that calcitonin and

vasopressin in porcine kidney cells (Nagamine et al.,
1983) and estrogen in breast carcinoma cells (Mira-y-Lopez
and Ossowski, 1987) induced urokinase mRNA expression.
Glucocorticoid has been shown to depress the expression of
urokinase activity in cultured cells (Busso et al., 1987).
Dexamethasone also decreased the urokinase mRNA levels in
normal and several malignant tumor cells (Medcalf et al.,
1986).

Growth factors, such as epidermal growth factor

(EGF) (Boyd, 1989; Niedbala and Sartorelli, 1989),
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platelet-derived growth factor (PDGF) (Stoppelli et al.,
l986), and interferon (IFN-gamma) (Collart et al., 1986)
increased the levels of urokinase rnRNA in cultured cancer
cells.

Transforming growth factor beta gave dual effects,

in that it stimulated urokinase secretion in certain
malignant cell lines (Keski-Oja gt al., 1988) and it
decreased the secretion of urokinase in bovine endothelial
cells (Saksela et al., 1987).

The transcriptional

increase of urokinase by hormone or growth factor is
mediated through the cAMP pathway (Saksela and Rifkin,
1988).

The 5'-nontranscibed regions of murine, porcine,

and human urokinase genes were found to contain
dodecanucleotides homologous to cAMP regulatory sequences
(Degen et al., 1987; Riccio et al., 1985; Nagamine et al.,
1985).

The tumor promoter, phorbol myristate acetate

(PMA) also increased urokinase rnRNA synthesis in various
carcinoma cells (Kelly et al., 1983; Degen et gl., 1985;
Collart et al., 1986), transformed cells (Belin et al.,
1984), and chicken embryo fibroblasts (Bell et al., 1990).
The increase of urokinase rnRNA level by PMA stimulation
was parallel to the increase of c-myc transcription
(Stoppelli et al., 1986).

The increase occurred within 30

minutes and peaked 2-4 hour after the PMA treatment
(Stoppelli et al., 1986).
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The regulation of urokinase activity is also
modulated by the urokinase specific cell surface receptor.
Another regulatory mechanism for urokinase activity is the
secretion of plasminogen activator inhibitors (PAis).
Three of the inhibitors, PAI-1, PAI-2, and protease nexin
are reported to regulate plasminogen activator activity by
rapid inhibition in vivo (Saksela and Rifkin, 1988).
Urokinase can regulate a variety of physiological
events that require extracellular proteolysis, such as
fibrin clot lysis, tissue remodeling, and cell migration
(reviewed by Dano et al., 1985).

Proteolytic degradation

of extracellular matrix components starts with activation
of plasminogen by plasminogen activator, subsequently the
formation of plasmin, and activation of procollagenase to
collagenase by plasmin as discussed previously.
Involvement of urokinase in cell migration is observed in
vitro.

It was shown that the continuously migrating,

wounded endothelial cells have increased urokinase
activity (Pepper et al., 1987).

Another physiological

process involving urokinase may be angiogenesis.
Urokinase has a function in the formation of new blood
vessels supplying the newly formed tumor with nutrients
required for rapid growth (d'Amore, 1988; Goldfarb et al.,
1986).

Lastly, urokinase may be involved in ovulation.
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Hormones associated with ovulation such as follicle
stimulating hormone (FSH) and luteinizing hormone (LH),
stimulate plasminogen activator (Ny et al., 1985; canipari
et al., 1987).

The regulation of urokinase activity is

also shown in pathological processes such as inflammation,
pemphigus, cancer, and metastasis (Dano et al, 1985).

urokinase and Tumor Cell Metastasis
Indirect evidence in support of a role for urokinase
in metastasis has been shown by multiple studies and is
reviewed by Dano et al.

(1985).

An increase in urokinase

gene expression or an enhanced urokinase synthesis/
secretion have been observed in metastatic variant cell
lines such as lung and breast carcinomas (Sappino et al.,
1987), mammary adenocarcinomas (Ramshaw et al., 1986;
Pereyra-Alfonso et al., 1988; Burtin et al., 1987), Lewis
lung carcinoma (Eisenbach et al., 1985), mammary carcinoma
(Pauli et al., 1987), human malignant melanoma (Markus et
al., 1984), and murine fibrosarcoma (Nagy and Grdina,
1989).

Furthermore, many of the solid tumors of lung

(Markus et al., 1980), prostate (Kirchheimer et al., 1985;
Camiolo et al, 1987; Gaylis et al., 1989), breast (Duffy
et al., 1988), stomach (Szczepanski et al., 1982),
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digestive tract (Noshino et al., 1988), and colon (de
Bruin et al., 1987) showed increased secretion of
urokinase as compared to their untransformed counterparts.
Treatment of cells with tumor promoters (Degen et al.,
1985; Stoppelli et al., 1986), tumor viruses (Unkeless et
al., 1973, Skriver et al., 1982), and src oncogene product
(Bell et al., 1990) also increased the gene expression or
enhanced the secretion of urokinase from cells in vitro.
There have been a number of studies that show a
correlation between plasminogen activator production and
metastasis in murine Bl6 melanoma cell lines.

Carlsen et

al. (1984) isolated clonal tumor cell populations which
produced various levels of plasminogen activator activity
and determined the metastatic potential of the isolated
clones by a lung colonization assay.

Their results showed

a strong correlation between production of plasminogen
activator activity and metastatic potential.

Wang et al.

(1980) also demonstrated that murine Bl6-Fl0 cells, a
highly metastatic subline of the Bl6 cell line, produced a
significantly greater amount of plasminogen activator
activity than the Bl6-Fl subline of lower metastatic
potential.

This result, however, is in contrast to the

work of Nicolson et al. (1976) who found that there was
essentially no difference in plasminogen activator
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activity between B16 variant cell lines.
A recent study showed that transf ected mouse L
cells expressing the human urokinase gene demonstrated an
increased degradation of extracellular matrix protein and
invasion of a Matrigel basement membrane.

This work

indicated that urokinase expression ,may be sufficient to
provide an invasive phenotype in the cell (Cajot et al.,
1989).
Immunocytochemical studies have also been used to
indicate the importance of urokinase activity in tumor
cell metastasis (Pollanen et al., 1987).

Skriver et al.

(1984) reported an increased urokinase level by means of
immunohistochemical staining in areas close to or in
contact with normal cells of the surrounding tissue being
invaded by the tumor cells.
Since type IV collagen is a major constituent of
basement membrane, it has been considered as an important
substrate for tumor invasion.

Type IV collagenase, which

is activated from procollagenase by plasmin, degrades type
IV and type V collagen and is therefore believed to have
an important role in the invasion of tumor cells through
the extracellular matrix and basement membrane (Liotta et
al., 1980; Goldfarb and Liotta, 1986; Reich et al., 1988;
Schultz et al., 1988).
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The human tissue inhibitor metalloproteinase
(TIMP), a glycoprotein with a molecular weight of 28,000,
is an inhibitor of metalloproteinases such as type I
collagenase, type IV collagenase, and stromelysin.

TIMP

has been shown to inhibit lung colonization by Bl6-Fl0
cells in vivo (Schultz et al., 1988).

Similar results

were reported with a synthetic collagenase inhibitor that
reduced the lung lesion in the same system (Reich et al.,
1988).

In addition, Khokha et gl. (1988) found that

transfection of an antisense RNA, complementary to the
mRNA encoding the collagenase inhibitor (TIMP), changed
the non-metastatic and non-tumorigenic mouse 3T3
fibroblasts, to the metastatic and tumorigenic phenotype
that has the ability to colonize the lungs of nude mice.
Whereas the majority of reports support a positive
correlation between metastatic potential and urokinase
activity, there exist other reports which show a lack of
such a correlation.

One report stressed that the only

proteinase secreted by malignant tissue was the cathepsin
B-like thiol proteinase (Rechlies et gl., 1980).

Others

reported a decreased plasminogen activator activity in the
plasma of tumor-bearing patients compared to normal
subjects (Colombi et al., 1984).

Another study reported

that plasminogen activator was enriched in the tumor cell
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membranes, however serine inhibitors did not abrogate
collagenolytic activity (Zucker et al., 1985).
one of the questions regarding the possible role of
urokinase in the metastatic process is whether urokinase
activity is required in the early steps such as
intravasation or during the later steps such as
extravasation.

Earlier work of Ossowski and Reich (1983)

showed that the injection of an antibody to urokinase into
the chick embryo prevented cells, which were placed on the
chorioallantoic membrane, from metastasizing to the
embryonic lung.

However, if the human HEp2 tumor cells

were placed directly into a vein, the urokinase antibody
had no inhibitory effect on lung colonization (Ossowski,
1988).

These results may indicate that urokinase is only

required for the intravasation step into the blood
vessels, but not for extravasation out of the blood
vessels (Ossowski, 1988).
Contrary to this, several other studies reported
that an increase in urokinase activity is correlated with
increased lung colonization following i.v. injection,
urokinase therefore plays a causal role in the
extravasation step of the metastatic cascade.

Hearing et

al. (1988) showed that Bl6 cells pretreated with antibody
to urokinase on their cell surf aces showed decreased
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numbers of metastases and that pretreatment of Bl6-Fl0
cells with plasmin, which converts single chain urokinase
to the more active two chain form of urokinase, increased
the numbers of metastases in the lung colonization assay.
very recently, Axelrod et al. (1989) expressed the
urokinase gene in H-ras-transf ormed NIH3T3 cells by
transfection of recombinant gene, and found that the
increase in urokinase gene expression resulted in a large
increase in pulmonary metastasis following tail vein
injection in nude mice.

Also Brunner et al.

(1989)

reported that mouse bladder carcinoma cells transf ected by
Ha-ras cells produced a 3-f old increase in urokinase
activity in cell lysates and 3-fold increase in cell
surface-associated urokinase activity.

This particular

clone induced a 6-fold increase in lung colonies.

Urokinase Receptor
A specific cell surface receptor with high affinity
for urokinase has been first identified in human blood
monocytes (Vassalli et al., 1985) and is present on a
variety of normal cells, such as fibroblasts, endothelial
cells, granulocytes, spermatozoa, and a number of
malignant tumor cells (Testa and Quigley, 1988; Stoppelli
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gt al., 1986; Vasaalli et al., 1985).

It has been

purified from several cell lines (Needham et al., 1987;
Nielsen et al., 1988; Estreicher et al., 1989).

The

receptor appears to be a 55-60 Kd glycoprotein (Nielsen et
al., 1988).

The number of receptors on cells, such as

monocytes or fibroblasts is about 10 5 sites per cell
(Blasi et al., 1986).

The urokinase receptor binds to the

amino terminal fragment (ATF) of the single chain form of
prourokinase or to the two chain form of urokinase
(Stoppelli et al., 1985).

More precisely it binds within

the first 32 residues of the growth factor domain in
urokinase (Appellal et al., 1987).

Therefore, the binding

of urokinase is completely independent of the catalytic
domain which is located in carboxyl terminal of the
urokinase molecule (Stoppelli et al., 1985; Appella et
al., 1987).

The 33 Kd urokinase, generated by plasmin

from the 54 Kd urokinase, does not bind to the receptor
(Needham et al., 1987).
It has been reported by immunofluorescence,
immunoprecipitation, and surface iodination assays that
the same cells have both secreted and membrane associated
urokinase activities (Stoppelli et al., 1986).

This

suggests that prourokinase might be initially secreted
into the extracellular space with subsequent binding to
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the specific receptor via an autocrine mechanism.

When

bound to its specific receptor, urokinase is not
internalized so its enzymatic activity is retained.

Mild

acid treatment releases the receptor bound urokinase from
the cell surface (Stoppelli et al., 1986).
The binding of urokinase to its cellular receptor
is shown to be extremely specific.

Any other related

proteins, such as epidermal growth factor (EGF), factor IX
and X, tissue PA, plasminogen, and thrombin do not compete
for binding with the amino terminal fragment (ATF) of
urokinase or with high molecular weight urokinase (Blasi
et al., 1986; Blasi, 1988).

Urokinase binding also shows

species specificity (Stoppelli et al., 1986; Estreicher et
al., 1989).

Murine urokinase binds to murine sperm cells

but not to human cells (Huarte et al., 1987).
The binding of urokinase to its receptor is shown
to be increased by epidermal growth factor (EGF) treatment
of the carcinoma cells (Blasi et al., 1986; Boyd, 1989).
Phorbol myristate acetate (PMA) has been shown to increase
urokinase receptor synthesis in a time and concentration
dependent manner.

PMA treatment also caused a decrease in

affinity of the urokinase receptor, suggesting another way
of regulating the interaction between urokinase and its
receptors (Picone et al., 1988).
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The function of the urokinase receptor has not been
established, however, possible advantages have been
suggested.

First, since the carboxyl terminal domain

remains exposed on the cell surface upon receptor binding,
urokinase binding might stimulate localized proteolytic
activity (Stoppelli

~al.,

1985; Pollanen et al., 1990).

secondly, the receptor bound enzyme might be protected
from inactivation by inhibitors.

It has been shown that

plasmin generated from the cell bound plasminogen is less
susceptible to inhibitors than its fluid phase counterpart
(Plow et al., 1986).

Thirdly, the binding of urokinase to

the cell surf ace might concentrate other substrates of the
multistep pathway, and subsequently increase the rate of
the cascade reaction (Moscatelli and Rifkin, 1988).
A possible role of urokinase binding to the
receptor has been shown by several investigators.

As

stated earlier, urokinase has a growth factor domain in
its amino acid sequence (Verde et al., 1984) which might
provide the mitogenic activity of urokinase.

The binding

of urokinase to its receptor seems to be necessary for the
growth stimulation of certain cell lines.

It was

demonstrated that the 54-Kd urokinase which binds to its
receptors stimulated the growth and proliferation of human
epidermal cells (Kirchheimer

~al.,

1989) and uterine and
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ovarian cancer cells (Takada and Takada, 1989), whereas
the 33-Kd urokinase fragment, which lacks the growth
factor domain and contains only the active-site domain,
did not stimulate cell proliferation (Kirchheimer et al.,
1989).
A question regarding the role of urokinase in
metastasis concerns its possible location of action.
Recent work has shown that many tumor cells contain
urokinase receptors on their cell surfaces (Needham et
al., 1987; Stoppelli et al., 1986).

Likewise, an increase

in cell surf ace urokinase receptor has been correlated
with an increased metastatic potential (Boyd et al.,
1988).

In vivo invasion assays with chick embryo

chorioallantoic membrane (CAM) showed that the invasive
ability of human tumor cells was augmented by saturating
their receptors with exogenous urokinase.

The stimulation

of urokinase production in the absence of binding to cell
receptors did not enhance invasiveness (Ossowski, 1988).
Boyd et al.

(1988) determined the levels of urokinase and

its receptor in colon carcinoma cell lines of different
differentiation degrees, and found aggressive metastatic
cell lines expressed a higher number of receptors and a
higher level of secreted endogenous urokinase activity
than more indolent cell lines.

Chapter III
MATERIALS AND METHODS
cell Culture

~

The Bl6-Fl and Bl6-Fl0 cells (Fidler, 1975) were
kindly provided by Dr. I.J. Fidler, M.D. Anderson Medical
center, University of Texas, Houston, TX.

Cells were

grown in Eagle's minimal essential medium (MEM)
supplemented with 10% heat-inactivated fetal bovine serum
(FBS) (Flow Laboratory, McLean, VA), 1% MEM nonessential
amino acids (Gibco Laboratories, Grand Island, NY), 1 rnM
sodium pyruvate, 1% MEM vitamin solution (Gibco
Laboratories), 75 units/ml of penicillin and 75 ug/ml of
streptomycin sulfate (Gibco Laboratories).
incubated at 37 C in 5%

co 2

Cells were

saturated with water vapor and

were maintained by changing the medium every three days
and subculturing at a 1:3 ratio at confluence.

For the

subculture, cells were detached from the flasks by
incubation with 1 rnM ethylenediamine tetracetic acid
(EDTA) in phosphate buffered saline (PBS) for several
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minutes.

The total number of viable cells were determined

by trypan blue exclusion in a hemocytometer (C.A. Hausser

and son, Philadelphia, PA).

BSV2-uPA Plasmid Construction

The plasmid pSV2-uPA containing the human
preprourokinase plasminogen activator coding sequences in
the sense direction was made from two plasmids, pSV2-dhfr
and pRdzbuktt.

pSV2-dhfr was purchased from American

Tissue Culture Center, Rockville, Md. and pRdzbuktt was a
gift of Dr. Michael E. Reff, Smith Kline & French & Co.,
King of Prussia, PA.

The plasmid pRdzbuktt is a mammalian

expression vector containing the full length cDNA for
human preprourokinase, Rous sarcoma virus (RSV) long
terminal repeats (LTR) promoter, a bovine growth hormone
(BGH) polyadenylation signal, the dihydrofolate reductase
(dhfr) terminator, the pBR322 origin of replication, and
an ampicillin resistant gene (Figure 1).

pSV2-dhfr is a

mammalian expression vector containing the dihydrofolate
reductase (dhfr) gene, a SV40 early and late gene
promoters, a SV40 polyadenylation signal, the pBR322
origin of replication, and an ampicillin resistant gene.
The strategy of plasmid construction, as shown in Figure
2, was to replace the dihydrofolate reductase (dhfr) gene
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Figure 1.

Structure of the plasmid pRdzbuktt

The plasmid pRdzbuktt contains the full
length cDNA for human preprourokinase, Rous sarcoma
virus (RSV) long terminal repeats (LTR) promoter, a
bovine growth hormone (BGH) polyadenylation signal,
the dihydrofolate reductase (dhfr) terminator, the
pBR322 origin of replication, and an ampicillin
resistant gene.

The human preprourokinase gene can

be retrieved from the plasmid by digestion with
HindIII and SacI.

The transcription is clockwise in

the 5' to 3' direction.

Restriction enzymes with

unique recognition sites are shown on the map.
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Figure 2.

construction of human preprourokinase

expression vector pSV2-uPA containing SV40 early
gene promoter
The human 1021 base pair preprourokinase cDNA
gene (uPA) was obtained by digestion of plasmid
pRdzbuktt with SacI and HindIII.

Plasmid pSV2-dhfr

was digested with HindIII and BglII to remove the
dhfr gene.

The uPA sequence was ligated to the

large fragment (4249 base pairs) of the pSV2 plasmid
to make the pSV2-uPA expression plasmid containing
human preprourokinase gene in a sense direction with
respect to the SV40 early gene promoter.
Transcription is clockwise in the 5' to 3'
direction.

The protein coding sequences are shown

in hatched area.
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of pSV2-dhfr with the preprourokinase gene of pRdzbuktt in
the sense orientation relative to the SV40 early gene
promoter.

In order to remove the dhfr gene from pSV2-

dhfr, the pSV2-dhfr was digested with HindIII and BglII.
Both cohesive ends were repaired to give blunt ends by
incubation with 5 units of T4 DNA polymerase I

(Boehringer

Mannheim Biochemicals, Indianapolis, IN) and 0.5 mM of the
mixture of dATP, dGTP, dCTP, TTP (Sigma Chemical Co.) in
an assay buffer provided by the manufacturer, at 37°C for
30 minutes.

The repaired DNAs were then treated with 10

units of alkaline phosphatase from calf intestine
(Boehringer Mannheim Biochemicals) to prevent self
ligation, by incubation for 1 hour at 50 C in the assay
buffer.

The repaired DNA fragments were separated by

electrophoresis in 0.8% agarose gel.

The 4249 base pairs

of large fragment DNA which contains the entire pSV2-dhfr
sequences, except for the dhfr gene, was eluted from
agarose gel using the IBI Analytical Electroeluter
(International Biotechnologies Inc., New Haven, CT).
To isolate the human preprourokinase cDNA from the
plasmid pRdzbuktt, the pRdzbuktt was digested with HindIII
and SacI, blunt ended as described previously for pSV2
vector, and separated by electrophoresis.

The small

fragment DNA of pRdzbuktt which contains 1021 base pairs
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corresponding to the preprourokinase coding sequences was
eluted.

The pSV2-vector fragment and human

preprourokinase fragment, were ligated overnight at room
temperature by 2 units of T4 DNA ligase (IBI, New Haven,
CT) in the assay buffer provided by the manufacturer.

The

ligated DNA was then transformed in E-coli strain HBlOl.
prior to transformation, the E-coli was cultured in SOB
medium (2% Bacto tryptone, 0.5% Bacto yeast extract, 10 mM
NaCl, 2.5 mM KCl, 10 mM MgC1 2 , 10 mM Mgso 4 ), resuspended
in RFl buffer (lOOmM RbCl, 50 mM MnC1 2 , 30 mM potassium
acetate, lOmM CaC1 2 .2H 2 o and 15% glycerol), then in RF2
buffer (10 mM MOPS, 10 mM RbCl, 75 mM CaC1 2 .2H 2 , 15%
glycerol) to improve transformation efficiency (Hanahan,
1983).

Ampicillin resistant clones were selected and

grown in LB medium with 50 ug/ml of ampicillin.
Plasmid DNAs of selected clones were screened for
the insertion of the preprourokinase gene by restriction
endonuclease digestion with BglII and were rescreened for
the pSV2-uPA in the sense orientation by restriction
endonuclease digestions with BamHI, PstI, and PvuII.

The

clone with the correct digestion fragments for pSV2-uPA
were amplified in the presence of chloroamphenicol (170
ug/ml).

The plasmid DNA from the selected clone was

prepared in large scale by the lysis of the E-coli cell
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wall with 0.2 N NaOH/1% SDS and plasmid DNA extraction
with isopropanol.

The prepared DNA was purified by

centrifugation to equilibrium in cesium chloride-ethium
bromide density gradient (Maniatis et al., 1982) for
transfection.

The plasmid structure and the restriction

digestion map of the constructed pSV2-uPA is shown in
Figure 3.

The final plasmid structure was confirmed by

additional restriction endonuclease digestions with BamHI,
PvuII, BglI, EcoRI, and Pstl and a double digestion with
BglII and HpaI.

pCLH3AXBPV-uPA Plasmid Construction

The plasmid pCLH3AXBPV-uPA containing the human
preprourokinase plasminogen activator gene in the sense
direction was similarly prepared from pRdzbuktt and
pCLH3AXBPV as described for pSV2-uPA.

The plasmid

pCLH3AXBPV, obtained from Dr. Gordon (Integrated Genetics,
Framingham, MA) (Reddy et al., 1987), contains the bovine
papilloma virus-1 (BPV-1) genome, mouse metallothionein
(MT-1) promoter, a SV40 polyadenylation signal, the pML-1
(a derivative of pBR322 origin of replication), and an
ampicillin resistant gene.

The structure of the plasmid

pCLH3AXBPV is shown in Figure 4.

The pCLH3AXBPV was

linerized by restriction endonuclease digestion with XhoI.
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Figure 3.

structure of the plasmid pSV2-uPA

The plasmid pSV2-uPA contains the full length
cDNA for human preprourokinase in the sense
orientation, SV40 early and late gene promoters, a
SV40 polyadenylation signal, the pBR322 origin of
replication, and an ampicillin resistant gene.

The

SV40 early promoter directs the expression of the
inserted human preprourokinase gene.

The

transcription is clockwise in the 5' to 3'
direction.

The outside plasmid circle,

corresponding to the inner circle, shows several
restriction enzymes used to verify the constructed
pSV2-uPA structure.
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Figure 4.

Structure of the plasmid pCLH3AXBPV

The plasmid pCLH3AXBPV contains the bovine
papilloma virus-1 (BPV-1) genome, the mouse
metallotheionine (MT-1) promoter, a SV40
polyadenylation signal, a derivative of the pBR322
origin of replication (pML-1), and an ampicillin
resistant gene.

The plasmid was linerized by the

restriction endonuclease digestion with XhoI to
insert human preprourokinase gene.

Several

restriction enzymes used to verify the plasmid
structure are shown on the map.
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The pRdzbuktt was digested with HindIII and SacI and the
human preprourokinase cDNA was separated by
electrophoresis and eluted from the agarose gel.

The

pCLH3AXBPV vector and the human preprourokinase fragment
were repaired to blunt ends with T4 DNA polymerase and a
mixture of four deoxynucleotide triphosphates and the two
ends were ligated.
Figure 5.

The construction scheme is shown in

The ligated DNA was transformed in E-coli and

the ampicillin resistant clones were selected.

The

selected clones were screened for pCLH3AXBPV-uPA by the
restriction endonuclease digestions with HpaI, HindIII,
and EcoRI.

The final plasmid construction was confirmed

by the additional restriction digestions with BamHI,
PvuII, and a double digestion with PvuI and PstI.

The

plasmid structure and the restriction digestion map of the
constructed pCLH3AXBPV-uPA is shown in Figure 6.

pSV2-ASuPA Antisense Plasmid Construction

The plasmid pSV2-ASuPA containing the 5'end 265base-pair of preprourokinase sequence in the antisense
direction was similarly prepared from pSV2-dhfr and
pRdzbuktt as shown in Figure 7.

The pSV2-dhfr was

digested with HindIII and BglII and the vector fragment of
pSV2 was separated by electrophoresis and eluted from the
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Figure 5.

Construction of human preprourokinase

expression vector pCIJl3AXBPV-uPA containing bovine
papilloma virus-1 (BPV-1) and metallothionein-1 (MT1) promoter
The human 1021 base pair preprourokinase cDNA
gene (uPA) was obtained by digestion of plasmid
pRdzbuktt with Sacl and HindIII.

The plasmid

pCLH3AXBPV was linerized by the digestion with XhoI.
The uPA sequence was ligated to the linear
pCLH3AXBPV to make the pCLH3AXBPV-uPA expression
plasmid containing human preprourokinase gene in a
sense direction with respect to the MT-1 promoter.
Transcription is clockwise in the 5' to 3'
direction.

The hatched area represents the

preprourokinase coding sequences.
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Figure 6.

Structure of the plasmid pCLH3AXBPV-uPA

The structure of plasmid pCLH3AXBPV-uPA is
identical with that of pCLH3AXBPV except the full
length cDNA for human preprourokinase was inserted
in the sense orientation at XhoI site.

The MT-1

promoter directs the expression of inserted human
preprourokinase gene.

The transcription is

clockwise in the 5' to 3' direction.

The outside

plasmid circle, corresponding to the inner circle,
shows several restriction enzymes used to verify the
constructed pCLH3AXBPV-uPA structure.
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Figure 7.

construction of human urokinase antisense

gene expression vector pSV2-ASuPA.
The human 5'end 265 base pairs of
preprourokinase cDNA was obtained by digestion of
plasmid pRdzbuktt with HindIII and NcoI.

Plasmid

pSV2-dhfr was digested with HindIII and BglII and
the large fragment was purified.

Two fragments were

ligated at HindIII sites in an antisense direction.
The cohesive ends of ligated DNA, NcoI and

~II

sites, were blunted by T4 DNA polymerase followed by
blunt ligation.

Transcription is clockwise in the

5' to 3' direction.
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agarose gel.

The pRdzbuktt was digested with HindIII and

H9.QI and 265-base-pair fragment containing the human
preprourokinase sequence was purified and eluted from the
agarose gel.

Two purified fragments were ligated at the

HindIII site which resulted in a 265-base-pair fragment
~

attached to pSV2-dhfr digest in an antisense orientation
with respect to the SV40 early gene promoter.

The

cohesive ends of the ligated DNA were blunted with T4 DNA
polymerase and a mixture of four deoxynucleoside
triphosphates, ligated, and then transformed in HBlOl.
The selected ampicillin resistant clones were analyzed for
the correct orientation by restriction endonuclease
digestions with BglI, PstI, and PvuII.

The final pSV2-

ASuPA plasmid construction was confirmed by additional
restriction digestions with BglI and PstI and double
digestions with PvuII-BamHI, BamHI-EcoRI, EcoRI-HpaI and
HpaI-PvuI.

The plasmid structure and the restriction

endonuclease digestion map of the constructed pSV2-ASuPA
structure is shown in Figure 8.

DNA Transf ection
DNA transf ection was performed by the calciumphosphate coprecipitation technique of Graham and van der
Eb (1973), with modifications.

Twenty-four hours before
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Figure 8.

Structure of the plasmid pSV2-ASuPA

The plasmid pSV2-ASuPA contains the HindIII
and NcoI digestion fragment of human preprourokinase
in the antisense orientation with respect to the
SV40 early gene promoter, the SV40 early and late
gene promoters, a SV40 polyadenylation signal, the
pBR322 origin of replication, and an ampicillin
resistant gene.

The SV40 early promoter directs the

expression of the inserted human preprourokinase
antisense gene.

The transcription is clockwise in

the 5' to 3' direction.

The outside plasmid circle,

corresponding to the inner circle, shows several
restriction enzymes used to verify the constructed
pSV2-ASuPA structure.
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the transfection, approximately 5 x 10 5 cells were seeded
in 100 mm Petri dishes containing Eagle's MEM and 10%
heat-inactivated FBS.

The DNA used for transfection was

purified by alkaline lysis extraction followed by CsCl
density gradient centrifugation, and then dialyzed against
TE-buffer (Maniatis et al., 1982).

The DNA used for the

transfection was in the form of closed circular plasmid
DNA.

Bl6-Fl cells were cotransfected with 10 ug of

constructed plasmid containing the human preprourokinase
gene (pSV2-uPA, pCLH3AXBPV-uPA or pRdzbuktt) and 1 ug of
pSV2-neo (American Type Culture Collection).

Bl6-Fl0

cells were cotransfected with 10 ug of pSV2-ASuPA and 1 ug
of pSV2-neo.
used.

For the control, 1 ug of pSV2-neo alone was

The CaP0 4 /DNA mixture was prepared by combining DNA

with 2 M CaC1 2 in HBSP buffer (1.5 mM Na 2 HP0 4 , 10 mM KCl,
280 mM NaCl, 12 mM glucose, 50 mM HEPES, pH 7.05) and was
allowed to form a precipitate for 30 minutes at room
temperature without any disturbance.

All the solutions

except DNA were kept sterile prior to transfection.

The

CaP0 4 /DNA precipitate was then slowly added to the cells
•

•

•

in a dropwise manner and the cells were incubated at 37
in 5%

co 2

saturated with water vapor for 16 hours.

0

c

At the

end of the transfection period, the cells were shocked
with 15% sterile glycerol in HBSP buffer for 3 minutes at
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3 7°c.

The cells were then allowed to recover in MEM

supplemented with 10% heat inactivated FBS for 24 hours at
3 7°c.

The cells were subcultured at a 1:3 ratio and

transferred to MEM with 10% heat inactivated FBS
containing 1.5 mg/ml Geneticin (G-418) (Gibco
Laboratories, Grand Island, NY).

The cells were provided

with fresh MEM with 10% heat inactivated FBS containing
Geneticin every three days.

Two weeks after the

initiation of Geneticin treatment, the transfected cells
were monitored every day and about four weeks later the
surviving cell colonies were further processed.

Fibrin Overlay Assay for Plasminogen Activator
The transient expression of the urokinase gene of
the transfected cells were assayed by the fibrin overlay
assay for plasminogen activator with minor modifications
(Kenten et al., 1986).

Two days after the transfection,

the cells were detached and collected from the petri
dishes by incubation with 1 mM EDTA in PBS and then washed
twice in serum-free MEM.

The cell suspension solution

(70% MEM supplemented with 10% heat inactivated FBS, 30%
Hank's balanced salt buffer (Gibco Laboratories),
supplemented with 2.5% low-gelling-temperature agarose)
(type VII, A-4018, Sigma Chemical Co.) was prepared and
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incubated at 42°C until the agarose was dissolved.

To the

9 ml of cell suspension solution, 0.7 units of thrombin
(from bovine plasma, T-6759, 276 units/ml, Sigma Chemical

co.) and 5 x 10 4 cells were added and rapidly mixed by
inverting the test tube.

Then 1.5 ml of MEM supplemented

with 10% heat inactivated FBS containing 30 mg/ml
fibrinogen (from bovine blood, F-4753, Sigma Chemical Co.)
was rapidly added and the mixture was poured immediately
into 100-mm petri dish.
in 5%

co 2

The dishes were incubated at 37°C

saturated with water vapor for 24 hr.

After the

incubation, the number of clearing zones which represent
the presence of the cells that produce urokinase were
counted.

As a reference, C127 cells obtained from ATCC

were transfected with pCLH3AXBPV-uPA and assayed in the
same manner to detect urokinase activity in the
transfected cells as documented by Reddy et al. (1987).
For the positive control, 10 ul of human urokinase (High
molecular weight urokinase, #124, 80,000 IU/mg, from
American Diagnostica Inc., New York, NY) solution (3.6
ug/ml) was added dropwise on the agarose fibrin plate.

Immunoblot Detection of Hum.an urokinase Production by_
Transf ected Cell Colonies
The surviving colonies of transfected cells were
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analyzed for the production of human urokinase by a filter
immunoblot assay (McCracken and Brown, 1984) with
polyclonal antibody to high molecular weight human
urokinase (American Diagnostica, New Haven, CN, Antibody
#389).

This assay was not used quantitatively, but only

used to verify the presence of urokinase production in the
colonies.

Prior to the assay, the medium was removed from

the petri dish containing transf ected Bl6-Fl or Bl6-Fl0
colonies.

The cells were washed twice with serum free

medium (SFM), then 2.5 ml of SFM was added to the cell.
An autoclaved disc of teflon mesh (Spectrum Medical
Industries Inc., Los Angeles, CA) was placed over the cell
colonies and a sterile notched nitrocellulose membrane
filter disc (Millipore, Bedford, MA) was laid over the
teflon mesh.

The cell colonies were then incubated for 7

to 8 hours at 37°C.

After the incubation, the filter and

mesh were removed and the cells were re-fed with MEM
containing 10% heat inactivated FBS with Geneticin until
colony transfer.

The filters were soaked in Denhardt's

solution (0.02% Ficoll, 0.02% polyvinylpyrrolidone, 0.1%
ovalbumin in 150 mM NaCl, 10 mM sodium phosphate, pH 7.4)
for 16 hours at 4

0

c

to block any non-specific binding

sites, washed with PBS-Tween (PBS containing 0.05% Tween20), and then incubated with 1:500 diluted rabbit
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polyclonal antibody to human urokinase (American
oiagnostica Inc., New York, NY, antibody #389) in PBSTween containing 0.1% ovalbumin for 2 hours at room
temperature.

The filters were subsequently washed and

incubated with 1:300 diluted goat antirabbit IgG
conjugated with alkaline phosphatase (Biorad, Richmond,
CA) in PBS-Tween for 1 hour at room temperature.

After

the second antibody treatment, filters were again washed
and incubated with BCIP/NBT (5-bromo-4-chloro-3-indoyl
phosphate/nitroblue tetrazolium) solution (Biorad) in
carbonate buffer (0.1 M NaHC0 3 , 1.0 mM MgC1 2 , pH 9.8) for
alkaline phosphatase color development.

After the filters

were processed, photocopies and transparencies were made.

Ouantif ication of Urokinase Production .Qy ELISA
The transparencies made from the immunoblot filters
were aligned with original culture dishes and twenty
positive colonies, dark purple spots on the filters, were
selected.
dishes.

These were transferred to separate petri
The cells in each colony were picked up using

yellow Pipetman tips after they were released from the
Petri dishes by scraping under the microscope in a sterile
hood.

They were allowed to proliferate in MEM

supplemented with 10% heat inactivated FBS.

In order to
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select the colonies that produce the highest amount of
urokinase, the secretion of urokinase from each colony was
quantitated by IMUCLONE Urokinase Plasminogen Activator
ELISA Kit (American Diagnostica Inc., New York, NY).

This

ELISA Kit detects both single and two-chain urokinase
(IMMUCLONE uPA ELISA Kit manual, American Diagnostica
Inc.).

Forty hours prior to ELISA, 2.5 x 10 4 cells were

seeded in 25 mm petri dishes in serum free MEM and
0

incubated at 37 C.

A 100 ul aliquot of conditioned medium

was removed from each colony and added to the ELISA plate
wells coated with murine monoclonal antibody to human
urokinase (high and low molecular weight urokinase).
•

•

0

The

•

plates were incubated for 90 minutes at 37 C in the buffer
provided by the manufacturer.

The wells were then washed

and incubated with rabbit anti-human urokinase conjugated
with horseradish peroxidase at 37°C for 1 hour.

After

incubation with the second antibody, the substrate was
added for peroxidase color development and incubated for
30 minutes at room temperature.

After the final

incubation, the reaction was stopped with solution
provided and absorbances were read at 405 nm in an ELISA
microplate spectrometer {Minireader II, Dynatach Labs,
Inc., Alexandria, VA).

Each colony was tested in

triplicate and three separate experiments were performed.
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Sf>Uthern Blot Hybridization Analysis of B16-F1 and B16-F1

p$V2-uPA transf ected cells
The genomic DNAs of Bl6-Fl cells, pSV2-neo
transfected cells, and clone 7 (C7) of pSV2-uPA
transfected Bl6-Fl cells were isolated by standard methods
(Davis et al., 1986).

The genomic DNAs of Bl6-Fl and

transfected Bl6-Fl cells and the pSV2-uPA plasmid were
digested with BamHI or PstI and electrophoresed overnight
on a 0.8% agarose gel.

The DNAs were Southern blotted to

nitrocellulose filter (Trans-Blot Transfer Medium, BioRad) by the capillary transfer method.

For the cDNA

probe, pSV2-uPA was double digested with HpaI and PstI and
the DNA fragment containing the preprourokinase sequence
was purified by electrophoresis and DNA electroelution.
The probe was labeled with 32 P-dCTP by nick translation
(Nick Translation System, BRL, Life Technologies, Inc.,
Gaithersburg, MD).

Briefly, the probe DNA was added to

the reaction mixture containing dATP, dGTP, dTTP, and 32 PdCTP (ICN Biomedicals, Inc., Irvine, CA) and nick
translated by incubation with 1 U of DNA polymerase I and
100 pg of DNase I at 15

0

c

for 60 minutes.

The nick-

translated CTP was separated from unincorporated 32 Plabeled CTP by NICK-Column (Pharmacia Fine Chemicals,
Uuppsala, Sweden) which contains Sephadex G-50 DNA Grade.
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The nitrocellulose filter was hybridized with 32 P-labeled
probe in hybridization solution containing 5X Denhardt's
(lX Denhardt's

= 0.02% Ficoll, 0.02% polyvinylpyrrolidone,

0.02% BSA), 1% SDS, 100 ng/ml denatured salmon sperm DNA,
1 M NaCl/10 mM Na 3 Po 4 b uffer, pH 6.5, at 65

0

c

.

overnight.

The filter was then washed four times for 30 minutes each
wash with 0.2X SSC (lX SSC = 0.15 M NaCl, 0.015 M sodium
citrate, pH 7.0) containing 0.5% SDS, at 65

0

c

and exposed

to X-ray film (Kodak X-OMAT AR Diagnostic Film, Eastman
Kodak Co., Rochester, NY) at

0

-7o c

with an intensifying

screen (Dupont Cronex Lighting Plus GJ 220004, Dupont Co.,
Wilmington, DE).

To estimate the relative amounts of

hybridization, the autoradiographs were scanned by a Gel
Scan densitometer equipped with a Gilford Response UV-VIS
Spectrometer (Gilford Systems, Oberline, OH).

Southern Blot Hybridization Analysis of B16-F1 and Bl6-Fl
pSV2-neo and pRdzbuktt transf ected cells to detect pSV2neo incorporation
The genomic DNAs of Bl6-Fl cells and pSV2-neo
transfected cells, pSV2-neo and pRdzbuktt cotransfected
cells were similarly isolated.

The prepared genomic DNAs

and the plasmid pSV2-neo were digested with HindIII or
double digested with HindIII and BamHI or HindIII and
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£§.t_l, electrophoresed overnight on a 0.8% agarose gel, and
blotted to nitrocellulose filter.

For the cDNA probe,

psv2-neo was digested with HindIII and Pstl and the DNA
fragment containing the neo gene was used.

The probe was

labeled with 32 P-dCTP by nick translation.

The

nitrocellulose filter was similarly hybridized with the
probe and exposed to X-ray film.

southern Blot Hybridization Analysis of B16-F1 and B16-F1
pRdzbuktt transf ected cells to detect pRdzbuktt
incorporation
To detect the pRdzbuktt incorporation, the plasmid
pRdzbuktt and the isolated cell DNAs were digested with
HindIII or double digested with HindIII and Sac! or
HindIII and Pstl and were separated by electrophoresis.
DNAs were Southern blotted to nitrocellulose filter.

For

the cDNA probe, pRdzbuktt was double digested with Sac!
and HindIII and the fragment containing the human
preprourokinase gene was used for the hybridization.

The

probe was labeled with 32 P-dCTP by nick translation.

The

nitrocellulose filter was similarly hybridized with the
probe and exposed to X-ray film.
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~outhern

Blot Hybridization Analysis of B16-F10 and B16-

F10 Antisense Transf ected Cells

~

The genomic DNAs of B16-Fl0 cells, pSV2-neo
transfected cells, and antisense clones 10 (AClO) and 8
(AC8) of pSV2-ASuPA transfected Bl6-Fl cells were
similarly isolated, digested with PstI, and
electrophoresed on a 0.8% agarose gel.

The DNAs were

southern blotted to nitrocellulose filter.

For the cDNA

probe, pSV2-ASuPA double digested with HpaI and PstI and
the DNA fragment containing the preprourokinase sequence
was purified.
translation.

The probe was labeled with 32 P-dCTP by nick
The nitrocellulose filter was similarly

hybridized with the probe and exposed to X-ray film.

Northern Blot Hybridization Analysis of B16-Fl and B16-Fl
Cells Transfected with pSV2-uPA
The cytoplasmic RNAs of Bl6-Fl, Bl6-Fl pSV2-neo
transfected cells, and pSV2-uPA transfected cells (clone 7
and 10) were extracted by a standard method (Ausubel et
al., 1988).

Briefly, the cells were washed and collected

in cold PBS and lysed in ice-cold lysis buffer (50 mM
Tris-Cl, pH 8.0, 100 mM NaCl, 5 mM MgC1 2 , 0.5% Nonidet P40 in DEPC-treated water).

The contaminating proteins
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were denatured with proteinase K and the RNA was purified
bY phenol extraction.

The prepared RNAs were separated

overnight by electrophoresis in 1% agarose/0.02%
formaldehyde gel in MOPS buffer (0.2 M MOPS, 0.05 M sodium
acetate, 0.01 M EDTA).

The RNAs were transferred to

Nytran Nylon Membrane (Schleicher & Schuell, Keene, NH) by
the capillary transfer method, and immobilized by a
covalent bond using the UV crosslinking technique (UV
stratalinker 1800, Stratagene, La Jolla, CA).

For the

cDNA probe, pSV2-uPA was double digested with BamHI and
PstI and the DNA fragment containing preprourokinase
sequence was labeled with 32 P-dCTP by nick translation.
The Nytran filter was hybridized with 32 P-labeled probe in
hybridization solution containing 50% formamide, 2.5X
Denhardt's reagent, 200 ug/ml of denatured salmon sperm
DNA, 0.5% SOS, and 5X SSPE (lX SSPE = 0.18 M NaCl/10 mM
NaPo 4 , pH 7.7/1 mM EDTA) at 42°C overnight.

The filter

was washed twice in 6X SSPE and 0.5% SOS at room
0

temperature, twice in lX SSPE and 0.5% SOS at 37 C, and
once in lX SSPE and 0.5% SOS at 60°C.
0

exposed to X-ray film at -70 C.

The filter was

To rehybridize the blot,

the pSV2-uPA probe was removed by boiling the filter for
20 minutes in O.OlX SSPE/0.5% SOS and rinsing twice in 2X
SSPE.

For the internal standard control, the stripped
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filter was similarly hybridized with 32 P-labeled
Drosophila actin (Fryberg et al., 1983) obtained from Dr.
Mark Kelley (Loyola University Medical Center) and exposed
to X-ray film.

Assay of the Binding of Human Urokinase to the Human PC3Met Cell Line and the Murine B16-Fl Cell line
The binding of human urokinase to B16-Fl or PC3-Met
cells (obtained from Dr. James Kozlowski, Northwestern
University, Chicago, IL) was determined by the procedure
of Stoppelli et al.

(1985), with modifications.

For B16-

Fl cells, 5 x 10 5 cells were seeded in 2 ml of MEM
supplemented with 10% heat-inactivated FBS in 6-well plate
(Elkay Products, Inc., Shrewbury, MA) and incubated at 37°
C in 5%

co 2

for 24 hours prior to the assay.

For PC3-Met

cells (Kozlowski et al., 1984), 2.5 x 10 5 cells were
similarly seeded in Dulbecco's modified Eagle's medium
(DMEM) supplemented with 10% heat-inactivated FBS.

The

cells were gently washed twice with PBS containing 1 mg/ml
of bovine serum albumin (BSA).

In order to unmask

urokinase receptors on the cell surface, the cells were
incubated for 3 minutes at room temperature in 50 mM
glycine-HCl buffer, pH 3.0, containing 0.1 M NaCl, and
quickly neutralized with 0.5 M HEPES buffer, pH 7.5,
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containing 0.1 M NaCl (Stoppelli et al., 1986).

The acid

treated cells appeared undamaged and bound to the plates.
The cells were then washed twice with serum-free MEM
containing 20 mM HEPES, pH 7.5, and 1 mg/ml of BSA and
incubated for 1 hour at 37°C in the same buffer containing
4x10 4 cpm of 125 I labeled human urokinase (see below) to
which different concentrations of unlabeled human
urokinase (American Diagnostica Inc., high molecular
weight, #124, 80,000 IU/mg) were added.

After incubation,

the cells were washed four times with PBS containing 1
mg/ml of BSA and lysed by incubation in 20 mM HEPES
buffer, pH 7.5, with 1% Triton X-100 and 10% glycerol for
30 minutes at room temperature.

The lysed cells were

counted in a gamma-ray counter (1191 Gamma Trac, Tm
Analytic, Inc., Elk Grove Village, IL).

Nonspecific

binding was determined in the presence of excess (50 nM)
unlabeled human urokinase and subtracted from the each
experimental value.

Each experimental concentration was

performed in triplicate and the results were plotted as
the mean cpm ± standard deviation.

x Labeling

125

of Human Urokinase

Three Iodo-Beads (Pierce Chemical Co., Rockford,
IL) and 1 mCi of Na 125 I in NaOH (IMS300, Amersham Corp.,

61

Arlington Heights, IL) were incubated in 0.05 M KHP0 4 , 0.2
M NaCl, pH 7.5, at room temperature for 5 minutes with
gentle shaking.

Human urokinase (High molecular weight

urokinase, #124, 80,000 IU/mg from American Diagnostica
Inc., New York, NY), 50 ug, was added to the iodination
mixture and incubated at room temperature for 20 minutes
with gentle shaking.

The 125 I human urokinase was

separated from free Na 125 I by gel filtration through a 9
ml Bio-Gel P-6 column (100-200 Mesh, Bio-Rad Laboratories)
which was presaturated by washing with five column volumes
of the above buff er containing 2 mg/ml of BSA.

The

urokinase 125 I fractions were combined and dialyzed
extensively against 0.05 M KHP0 4 , 0.2 M NaCl buffer with 1

mM KI overnight and then against 0.05 M KHP0 4 , 0.2 M NaCl
buffer.

The amount of protein was determined by the BIO-

RAD Protein Assay Kit (Bio-Rad Laboratories) according to
the manufacturer's instruction.

Determination of Glycosylation of Human Urokinase

A Concanavalin A affinity chromatography column was
used to determine if human urokinase produced by
transfected murine cells was glycosylated.

Con A-

Sepharose (Pharmacia Fine Chemicals, Uuppsala, Sweden) (1
ml) was packed in a blue Eppendorf pipette tip and washed
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with 50 mM Tris buffer, pH 7.5.

The resin was further

prepared by washing with buffer containing 100 mM sodium
acetate, 1 mM NaCl, 10 mM cacl 2 , 10 mM MgC1 2 , pH 6.0.
conditioned medium, prepared by incubating 5x10 5 cells of
clone 7 of pSV2-uPA transf ected Bl6-Fl in 2 ml of serum
0

free MEM in a 6-well plate for 40 hours at 37 c, was
collected and applied to the ConA sepharose column.

The

column was washed with four column volumes of 50 mM Tris
buffer and then with the same buffer containing 0.5 M
alpha-methyl-D-mannoside (Sigma Chemical Co.) to elute the
glycosylated protein from the resin.

Fractions of 400 ul

were collected and assayed for human urokinase by the
IMUCLONE Urokinase Plasminogen Activator ELISA Kit
(American Diagnostica, Inc.) using a monoclonal antibody
to human urokinase, as described above.

Collection of Conditioned Medium for Quantification of
Urokinase Activity Secreted by. Cultured Cells
The cells were plated in 6-well cell culture plates
at a concentration of 2 x 10 5 cells per well in MEM
supplemented with 10% heat-inactivated FBS and incubated
overnight at 37°C in a 5% co 2 atmosphere.

The cells were

rinsed twice with serum free medium (SFM) and incubated
for 24 hours in SFM at 37°C in a 5% co 2 atmosphere.

The
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cell conditioned media was collected and the cells were
harvested and counted.

v..uorogenic Substrate Assay for Plasminogen Activator
A._ctivity
Plasminogen activator activity was measured by
fluorescence spectroscopy as described by O'Donnell-Tormey
and Quigley (1983).

Cells to be assayed were collected by

incubation with 0.25% of trypsin (Worthington Biochemical
corp., Freehold, NJ) in PBS containing 1 mM EDTA for few
seconds.

Cells were washed with PBS three times and

resuspended in HEPES buffer (5% dimethyl sulfoxide in 0.05
M HEPES, pH 7.4) at the concentration of 1 x 10 6 cells/ml.
Cell suspension solution (400 ul) was mixed with 170 ul of
HEPES buffer, 30 ul of fluorogenic substrate for
plasminogen activator, methoxysuccinyl-L-Gly-L-Gly-L-Arg7-amino-4-methylcoumarin HCl (Bachem Fine Chemicals, Inc.,
Torrance, Calif.) (final concentration of 10 mM).

The

release of 7-amino-4-methylcoumarin (AMC) from the
substrate was measured in a Perkin-Elmer MPF-44B
Fluorescence Spectrophotometer at an excitation wave
length of 380 nm and an emission wave length of 460 nm.
The linear release of AMC was recorded for 5 minutes and
the slope of the linear curve was measured.

To calibrate
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the instrument, 7-amino-4-methyl coumarine (Sigma Chemical
co.) was used as a standard.

For the standard curve,

different dilutions of human urokinase (High molecular
weight urokinase, #124, from American Diagnostica Inc.,
New York, NY) were used instead of cells.

chromogenic Substrate Assay for Plasminogen Activator
Activity
Plasminogen activator activity was measured
spectroscopically using a chromogenic substrate for
plasmin as previously described by Whur et al.

(1980).

Ten ul of cell conditioned media was added to 100 ul of
100 mM Tris buffer, pH 8.1, containing 5 ug of plasminogen
(Sigma Chemical Co.), 15 ug of S-2251 (H-D-Val-Leu-Lys-pnitroanilide, KabiVitrum, Stockholm, Sweden), and 0.1%
Triton X-100 in 96-well plates.

Plasminogen was treated,

prior to use, to inhibit any active plasmin activity by
incubating plasminogen with diisopropylfluorophosphate
(DFP) at 25 mM in 50 mM Tris buffer, pH 8.1, at 37°C for 1
hour and then extensively dialyzing against the same
buffer.

Plasmin activity was measured with DFP-treated

plasminogen to ensure plasmin activity was no longer
detected by the same assay.
16 hours at 37°C in a 5%

co 2

The plates were incubated for
atmosphere. After incubation,
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the p-nitroaniline absorbances, corresponding to substrate
hydrolysis by plasmin, were read at 405 nm in a
spectrometer (Minireader II, Dynatech Labs, Inc.,
Alexandria, VA).
To test the stability of urokinase gene expression
in the transfected cells in a longer period of time, one
of the flask of Clone 7 of pSV2-uPA transfected Bl6-Fl
cells were passaged more than 20 times.

The conditioned

medium was collected from that particular flask and
assayed for the plasminogen activator activity by the same
method.

Determination of the standard curve of

plasminogen activator activity and nonspecific activity
were included in each assay.
The nonspecific activity was determined in the
absence of cell conditioned medium and subtracted from
each experimental value.

For the background activity,

reaction buff er was used instead of plasminogen for the
assay.

Each experiment was performed in triplicate and

five separate experiments were assayed.

Plasminogen

activator activity was expressed in pg secreted in the
conditioned medium per cell per hour.

125 1-fibrin Plate Assay for Plasminogen Activator Activity
The procedure was similar to that described
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previously by Strickland and Beers (1976).

Bovine

fibrinogen (Sigma Chemical Co.) was iodinated with Nal251
by the same procedure as described above for the 1 25 1
labeling of human urokinase.

The specific radioactivity

of the fibrinogen was adjusted to 15,000 cpm/ug of
fibrinogen by the addition of unlabeled fibrinogen.

To

each well of a 24-well plate (Gibco Laboratories), 250 ul
of 125 1-fibrinogen in 50 mM Tris buffer, pH 8.1 (50,000
.

•

0

cpm per well) was added and dried in a 37 C dry oven for
two days.

Prior to use, wells were incubated with 500 ul

of MEM supplemented with 5% plasminogen-depleted FBS at 37°

c

in a 5%

co 2

atmosphere to convert fibrinogen to fibrin.

Plasminogen-depleted FBS was prepared by repeated
0

incubation of FBS at 56 C for 45 minutes.

Wells were

washed three times with 50 mM Tris buffer, pH 8.1 and
incubated for 2 hours with 100 ul of cell conditioned
medium, 75 ug of BSA and 10 ug of DFP treated plasminogen
0

(Sigma Chemical Co.) in the 300 ul of same buffer at 37 C
in a 5%

co 2

atmosphere.

At the end of the incubation

period, a 100 ul aliquot of supernatant was taken from
each well and counted in a gamma-counter.

Nonspecific

activity was determined in the absence of conditioned
medium and subtracted from each experimental value.

For

the background activity, reaction buffer was used instead
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of plasminogen for the assay.
included in every assay.

A standard curve was

Each experiment was performed in

triplicate and five separate experiments were assayed.
p1asminogen activator activity was expressed in pg
secreted in the conditioned medium per cell per hour.

Murine Lung Colonization Assay
The murine Bl6-Fl or Bl6-Fl0 melanoma lung assay
was performed in a similar manner as previously described
by Fidler (1978).

Transfected Bl6-Fl or Bl6-Fl0 cells

were grown to semi-confluency (80-90%) in MEM supplemented
with 10% heat inactivated FBS and harvested by the
addition of 1 ml of 1 mM EDTA in PBS, pH 7.4 at 37°C for 1
minute.

MEM supplemented with 10% heat inactivated FBS

was added, centrifuged, and resuspended in PBS.

The cells

were counted using a Coulter Counter (Coulter Electronics,
Inc., Hialeah, FL) and diluted to 5xlo 5 cells/ml.

The

viability of the cells was determined by counting trypan
blue exclusion.
injection.

The cells were maintained on ice prior to

A total of 26 female C57BL/6 mice, 6-8 weeks

old (Harlan Laboratories, Indianapolis, IN) were equally
divided into control and experimental groups.

Mice were

housed in the Loyola Medical Center Animal Research
Facility for one week prior to use.

A 0.2 ml aliquot of
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cell suspension (100,000 cells per mouse) were slowly
injected into the lateral tail vein of each mouse
while immobilized in a mouse vice.

The injection schedule

alternated between mice in the control group and mice in
the experimental group to minimize the variance in time.
The animals were sacrificed 17 days after the injection of
transfected cells by administering an overdose of ether.
The lungs were removed and fixed in Bouin's solution
(0.75% picric acid, 25% formaldehyde, 5% glacial acetic
acid) overnight.

The number of surface tumor colonies,

easily visible as black or white nodules on the yellow
Bouin's background, were counted under a dissecting
microscope.

Spontaneous Metastasis Assay
The assay of spontaneous metastasis from a foot pad
tumor was carried out by the procedure of Fidler (1986),
with minor modifications.

Cells were grown to semi-

confluency in MEM supplemented with 10% heat inactivated
FBS, harvested, and tested for viability, and counted as
described above.

Female C57BL/6 mice, 6-8 weeks old

(Harlan Laboratories) were housed in the Loyola Medical
Center Animal Care Facility for one week prior to use.
Mice were lightly anesthetized with ether and injected
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subcutaneously into a posterior footpad with 10 5 cells of
clone 7 of B16-Fl transf ected cells for experimental
animals or pSV2-neo transfected cells for a control.

The

cells for injection were suspended in 0.05 ml of PBS.

An

1/2 inch 27-gauge needle was inserted into the dorsal
aspect of the foot for injection.

Three weeks later,

after allowing the cells to grow into the primary site,
mice were lightly anesthetized with the inhalation
anesthetic, Metofane (Methoxyfurane) (Pitman-Moore, Inc.,
Washington Crossing, NJ) and the tumor-bearing foot was
amputated with a pair of scissors.

The wound was

cauterized and drawn together with wound clips (Becton
Dickinson & Co., Parsippany, NJ).

Mice were injected with

15 ug of Buprenex (Buprenorphine HCl, Reckitt & Colman
Pharmaceutical, Inc., Norwich, NY) to relieve the pain and
returned to their cages.

After an additional 3-4 weeks,

the animals were sacrificed by an overdose of ether.

The

lungs were removed and fixed in Bouin's solution
overnight.

The number of surface tumor colonies were

counted under a dissecting microscope.

Culture Qf. Lung Colony Tum.or Cells

C57BL/6 mice were injected with 100,000 cells of
Clone 7 of pSV2-uPA transfected B16-Fl cells or pSV2-neo
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transfected Bl6-Fl cells.
after injection.

Animals were sacrificed 17 days

The lungs were removed aseptically, cut

into small pieces with sterile razor blades, and plated in
vitro on petri dishes containing MEM supplemented with 10%
heat-inactivated FBS.

The medium was changed after the

cultures adhered to the petri dishes.

The cells were

maintained in the same manner as Bl6-Fl cells when the
cultures became confluent.

cytotoxicity Assay
The cytotoxicity assay was performed to test the
immunologic responses in C57BL/6 mice against transf ected
murine cells which produce human urokinase.

The procedure

is similar to that described by Hirschberg et al.

(1977).

Spleens were collected at the time of sacrifice from the
mice which were injected with transfected cells.
Lymphocytes were harvested from the spleens and served as
cytotoxic effectors.

The targets cells, Bl6-Fl

transfected with pSV2-neo or clone 7 of pSV2-uPA
transfected cells, were labeled with 51 cr.

Cytotoxic

effectors were mixed with target cells at the ratio of
50:1, 25:1, 12:1 or 6:1 and incubated for 4 hours at 37°C.
The mixture was centrifuged and the supernatant was
harvested and counted for radioactivity in a gamma counter
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and % specific release was calculated.

The spleen from

the uninjected animal and B16-Fl untransf ected cells were
used as a control .

.s_tatistical Analysis of Data
Numerical data was expressed as the mean ± standard
deviation or the mean ± standard error of several
determinations.

To compare the data between the control

and experimental groups, student t test and Mann Whitney
U-Test (nonparametric rank sum test) were used.

P values

of < 0.05 were considered to represent significant
difference between two groups.

Chapter IV
RESULTS
J.

The Production of Human Urokinase in Murine B16-Fl

Melanoma Cells and The Study of Its Effect on Tumor
cell Metastasis
Expression of Human Preprourokinase Gene
To express the human preprourokinase gene in B16-Fl
melanoma cells, the plasmid pSV2-uPA which contains human
preprourokinase cDNA in a sense direction with respect to
the SV40 early gene promoter, was prepared.

For the

synthesis of pSV2-uPA, the dihydrofolate reductase gene of
the plasmid pSV2-dhfr was replaced by the preprourokinase
gene isolated from the plasmid pRdzbuktt.

The detailed

steps involved in subcloning preprourokinase cDNA into
pSV2 vector are summarized in Figure 2.

The correct

plasmid which contained the preprourokinase gene in the
sense direction was selected by restriction endonuclease
digestion profile which is shown in Figure 3.
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To introduce the human preprourokinase gene into
Bl6-Fl melanoma cells, transfection technique was used.
Transf ection was carried out by using calcium phosphate
precipitation with DNA followed by a glycerol shock.
cells were cotransfected with plasmids pSV2-uPA and a
selection marker gene pSV2-neo in 10:1 ratio, or
transfected with the pSV2-neo alone for the control.

In

the pSV2-neo, SV40 early gene promotes the expression of
an aminoglycoside phosphotransferase from the E...... coli
transposable element Tn5.

Expression of aminoglycoside

phosphotransferase confers upon mammalian cells resistance
to the toxic aminoglycoside G-418 (Geneticin), a neomycin
analog.

Therefore the pSV2-neo recipient mammalian cells

gain the capability to survive in Geneticin upon
successful transfection.

To select transfected colonies,

cells were grown in the presence of Geneticin (G-418) for
four to five weeks.

The transfection efficiency in the

Bl6-Fl cell line by the transfection condition described
on Materials and Methods section is shown to be about one
transformant in 5,000 transfected cells when the closed
circular plasmid DNA was used for transfection.

The

linerized plasmid DNA gave significantly low transfection
efficiency (data not shown).

The efficiency of

transf ection was not increased by using a carrier DNA such
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as 10 ug/ml of salmon sperm DNA for transfection (data not
shown).

A change of fresh MEM prior to transfection did

not affect transfection efficiency (data not shown).
cells appeared to be damaged and were lifted off from the
petri dish if they were shocked longer than 5 minutes.
The best transfection results were obtained when the cells
underwent at least two cell divisions if thawed from the
frozen stock and appeared very healthy before the
transfection.
The surviving colonies expressing the neo gene were
assayed for the coexpression of the human preprourokinase
gene by a filter immunoblot assay as shown in Figure 9.
In this assay, all the proteins being secreted from the
colonies expressing preprourokinase gene were absorbed to
nitrocellulose filter.

The filter was treated with

polyclonal antibody to human urokinase to select for the
positive colonies that produce human urokinase.

Figure 9

shows that pSV2-uPA and pSV2-neo transf ected cells
generated many positive colonies detected by the dark
color development.

However pSV2-neo transfected control

cells show the absence of color development which
indicates these cells do not produce human urokinase.
Twenty positive colonies detected for human
urokinase secretion by filter immunoblot assay were
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Figure 9.

Filter i:mmunoblot analysis of transfected

B16-F1 cell colonies
Bl6-Fl cells were transfected with pSV2-neo
(top) or cotransfected with pSV2-uPA and pSV2-neo
(bottom).

Transfected cells were cultured in MEM

supplemented with 10% heat inactivated FBS
containing Geneticin (G-418).

Five weeks later,

nitrocellulose membrane filters were placed over the
cell colonies to absorb urokinase being secreted.
The filters were treated with rabbit polyclonal
antibody to human urokinase followed by goat antirabbi t IgG conjugated with alkaline phosphatase,
which were reacted with NBT/BCIP to give dark purple
color development.

The spots on the filters

correspond to the transf ected foci expressing human
urokinase.
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selected, transferred to separate petri dishes, and
expanded in MEM supplemented with 10% heat inactivated
FBS.

Secretion of human urokinase into the cell culture

medium from each colony was then quantitated by a sandwich
type ELISA using a monoclonal antibody against high
molecular weight human urokinase as the primary antibody
and polyclonal antibody against high and low molecular
weight human urokinase as the detecting antibody.
Monoclonal antibody to human urokinase has been reported
to identify the single-chain prourokinase as well as twochain urokinase (Sallerno et al., 1984).

The ELISA Kit

(American Diagnostica Inc.) was used for the assay to
detect both single and two-chain urokinase.

Table 1 shows

that clone 7, 8, 10, and 18 secreted the highest amount of
human urokinase out of 20 positive selected clones.

Bl6-

Fl or Bl6-Fl0 untransfected cells give absorption value
equal to zero, as no human urokinase is produced.
The incorporation of human preprourokinase gene to
genomic DNA of transfected cells was demonstrated by a
Southern blot hybridization assay as shown in Figure 10.
The DNAs were prepared from clone 7 of pSV2-uPA
transfected cells and Bl6-Fl untransfected cells, digested
with BamHI or PstI, separated by electrophoresis, blotted,
and probed with 32 P labeled human preprourokinase cDNA.
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Table 1.

Quantification of human urokinase production by

B16-F1 transfected cells with pSV2-uPA detected by ELISAa

Clone
No

Absorbance
(Mean±SD)

Clone
No

Absorbance
(Mean±SD)

Cl
C2
C3
C4
C5

1.79
0.25
1.17
0.72
0.87

±
±
±
±
±

0.06
0.03
0.01
0.04
0.04

Cll
Cl2
Cl3
Cl4
Cl5

2.71
0.14
2.81
0.13
0.34

±
±
±
±
±

0.15
0.15
0.06
0.02
0.05

C6
C7
C8
C9
ClO

0.09
4.24
2.97
0.10
3.43

±
±
±
±
±

0.03
0.28
0.12
0.03
0.13

Cl6
Cl7
Cl8
Cl9
C20

0.72
0.51
3.22
1.57
1.63

±
±
±
±
±

0.07
0.02
0.24
0.08
0.05

Bl6Fl

0.08 + o.03b

Bl6Fl0

0.08 ± o.o4b

aThe secretion of urokinase from each colony was
quantitated by IMUCLONE uPA ELISA Kit (American
Diagnostica Inc.) on conditioned media taken from the
cells incubated in the serum free media for 40 hours.
bvalue equal to zero as no human urokinase is produced by
murine Bl6-Fl cells which were not transfected with the
pSV2-uPA plasmid.
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Figure 10.

southern blot hybridization analysis of

DNA isolated from clone 7 of pSV2-uPA transf ected

B16-F1 and B16-F1 untransf ected cells
DNAs were isolated from clone 7 of
transf ected Bl6-Fl cells and untransf ected Bl6-Fl
cells.

The DNAs (10 ug) were cleaved with PstI or

BamHI and electrophoresed through 0.8% agarose gel.
A control pSV2-uPA plasmid preparation was similarly
digested with PstI or BamHI and different amounts
were loaded on the same gel.

The DNAs were

transferred to nitrocellulose and probed with 32 Plabeled HpaI-PstI fragment of pSV2-uPA.

Lanes 1-2

contain DNA made from 7 x 10 6 cells of clone 7 of
pSV2-uPA transf ected cells and lanes 3-4 contain DNA
made from 7 x 10 6 untransfected cells.

Lanes 5-6

contain DNA made from 3.5 x 10 6 cells of clone 7 and
lanes 7-8 from 3.5 x 10 6 untransfected cells.

Lanes

9-10, lanes 11-12, lanes 13-14 contain pSV2-uPA DNA
of 10, 5, 2 ng respectively.

Lanes 1,3,5,7,9,11,13

contain DNA digested with BamHI and lanes
2,4,6,8,10,12,14 contain DNA digested with PstI.
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The digestion of pSV2-uPA with BamHI generates two DNA
bands with base pairs of 4647 and 896 and the 32 P-labeled
probe hybridizes with both bands.

The digestion of pSV2-

uPA with PstI generates three DNA bands with base pairs of
2327, 2258, and 958 and the 32 P-labeled probe hybridizes
with 2327 and 2258 bands.

As shown in Figure 10, clone 7

DNA digested with BamHI (lanes 1 and 5) showed two DNA
bands of 4647 and 896 base pairs same as BamHI digested
pSV2-uPA (lanes 9, 11, and 13).

Again clone 7 DNA

digested with PstI (lanes 2 and 6) showed one combined
band of 2327 and 2258 base pairs same as PstI digested
pSV2-uPA (lanes 10, 12, and 14).

Therefore clone 7

demonstrates the restriction endonuclease digested bands
identical to those of pSV2-uPA while the untransf ected
cells (lanes 3, 4, 7, and 8) show the absence of these
bands.
The DNA copy numbers of human preprourokinase cDNA
in clone 7 were estimated from a densitometer scan of
autoradiographs by comparing the amounts of hybridization
of a 32 P-labeled probe to the genomic DNA of clone 7 cells
(lanes 2 and 6) with known amounts of pSV2-uPA plasmids
(lanes 10, 12, and 14).

Figure 11 demonstrates the

densitometer scan of lanes 2 (peak A), 6 (peak B+C), 10
(peak D), 12 (peak E), and 14 (peak F) of Figure 10
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Figure 11.

Densitometer scan of autoradioqraphs of

32 P hybridized to .the genomic DNA of clone 7 or
pSV2-uPA plasmid DNA
The DNA copy numbers of human preprourokinase
cDNA in clone 7 were estimated from a densitometer
scan of autoradiographs by comparing the amounts of
hybridization of a 32 -labeled probe to the genomic
DNA of clone 7 cells with known amounts of pSV2-uPA
plasmids.

Peak A (lane 2 of Figure 10) with peak

area of 12.9 represents DNA prepared from 7 x 10 6
cells, peak B+C (lane 6 of Figure 10) with peak area
of 7.12 represents DNA made from 3.5 X 10 6 cells.
Peaks D (lane 10 of Figure 10), E (lane 12 of Figure
10), and F (lane 14 of figure 10) which show peak
area of 15.0, 8.93, and 2.40 represent 10, 5, and 2
ng of pSV2-uPA DNA respectively.
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showing peak areas of 12.9, 7.12, 15.0, 8.93, and 2.40
respectively.

Peak A and peak B+C represent DNAs prepared

from 7 x 10 6 cells and 3.5 x 10 6 cells of clone 7.

Peaks

o,E, and F represent 10 ng, 5 ng, and 2 ng of pSV2-uPA
respectively, and accordingly approximately 1 x 10 9 , 5 x
108, 2 x 10 8 copies of pSV2-uPA.

By the comparison of

peak areas of A and B+C with D, E, and F, the copy numbers
of pSV2-uPA in clone 7 lanes were estimated.

The

estimated copy numbers were divided by the clone 7 cell
numbers from which the DNA was prepared to calculate the
copy numbers present per cell of clone 7.

The

calculations by the comparison of A with D, E, or F gave
copy numbers of 131, 123, or 168 respectively and by the
comparison of B+C with D, E, or F gave copy numbers of
149, 156, or 185.

On average, therefore, approximately

150 copies of pSV2-uPA were shown to be incorporated
within the genomic DNA of clone 7.
The expression of human preprourokinase mRNA was
determined by Northern blot hybridization assay as shown
in Figure 12.

The cytoplasmic RNAs from clones 7 and 10

of pSV2-uPA transfected cells, pSV2-neo transfected cells,
and untransfected Bl6-Fl cells were extracted, separated
by formaldehyde/agarose gel, transferred to filter, and
probed with 32 P-labeled human preprourokinase cDNA.

The

85

Figure 12.

Northern blot hybridization analysis of

RNA isolated from clone 7 and clone 10 of pSV2-uPA
transfected cells, pSV2-neo transfected cell, and
B16-F1 untransf ected cells
The cytoplasmic RNAs of B16-Fl, B16-Fl
transfected cells were extracted, separated by The
filter was hybridized with 32 P-labeled human
preprourokinase cDNA probe and exposed to X-ray
film.

The 2.3 Kb band on the clone 7 and clone 10

lanes demonstrates human urokinase mRNA expression,
while this band is absent in B16-Fl or B16-Fl pSV2neo transfected cell RNA.

For the internal

standard, 32 P-labeled Drosophila actin was used.
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ianes with clone 7 and 10 RNAs show distinct bands which
represent a 2.3 Kb mRNA of human preprourokinase gene
while the lanes with Bl6-Fl untransfected cells and pSV2neo transfected cells show absent of that band.

The

internal standard of 32 P-labeled Drosophila actin shows
that similar amounts of RNA were applied to each lane of
the gel.
Figure 13 shows a densitometer scan of
autoradiographs of a 32 P-labeled probe to the RNA of clone
7, 10 or pSV2-neo transfected cells.

The densitometer

scan of human urokinase RNA of clone 7 (lane 3 of Figure
12, peak A) and clone 10 (lane 4 of Figure 12, peak B)
gave the peak area of 1.71 and 1.88 respectively.

The

densitometer scan of Drosophila actin RNA of lane 3 of
Figure 12 (peak D+E) and lane 4 of Figure 12 (peak F+G)
gave the peak area of 0.97 and 1.27 respectively.

The

relative amount of human preprourokinase mRNA expression
in clone 7 and 10 was estimated by calculating the ratio
of peak areas of human urokinase to actin.

The ratio of

peak A/peak D+E (1.71/0.97) and peak b/peaks F+G
(1.88/1.27) gave the value of 1.76 and 1.48 which indicate
human preprourokinase mRNA expression of clone 7 and clone
10 respectively.

The ELISA data (Table 1) showed C7 and

Clo secreted human urokinase activity with absorbance
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Figure 13.

Densitometer scan of autoradiographs of

. 32 p hybridized to the RNA of clone 7, 10, or pSV2neo transfected cells
The relative amount of RNA of human
preprourokinase in clone 7 and clone 10 were
estimated from a densitometer scan of
autoradiographs by comparing the amounts of
hybridization of a 32 P-labeled probe to the internal
standard of Drosophila actin RNA.

In the top

figure, peak A (lane 3 of Figure 12) with peak area
of 1.71 represents human urokinase RNA prepared from
clone 7 cells, peak B (lane 4 of Figure 12) with
peak area of 1.88 represents human urokinase RNA
made from clone 10 cells.

In the bottom figure,

peaks D+E (lane 3 of Figure 12), F+G (lane 4 of
Figure 12) which show peak area of 0.97 and 1.27
represent Drosophila actin.
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value of 4.24 and 3.43 respectively.

The ratio of human

urokinase versus mRNA was calculated to be 2.41
(4.24/1.76) for C7 and 2.32 (3.43/1.48) for ClO.

The

ratio of mRNA expression and human urokinase secretion
between C7 and ClO is shown to be similar: 1.19
(1.76/1.48) for mRNA and 1.24 (4.24/3.43) for urokinase.

characterization of Human Urokinase produced

~

Murine

Cells
Human urokinase is a glycoprotein (Holmes et al.,
1985) whereas the murine urokinase lacks glycosylation
sequences and is not glycosylated (Belin et al., 1985).
Since the human urokinase is synthesized by transfected
murine cells, the possible glycosylation of the human
urokinase was tested by Concanavalin A column
chromatography, which tightly binds polysaccharides and
glycoproteins containing alpha-D-mannopyranosyl, alpha-Dglucopyranosyl and sterically related residues (Narasimha
et al, 1979).

Tightly bound glycoproteins can be eluted

by the addition of alpha-methyl-D-mannoside to the buffer
(Aspberg and Porath, 1970).

The added alpha-methyl-D-

mannoside will compete for the carbohydrate binding sites
on the ConA, and cause the dissociation of any bound
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glycoproteins.

The column eluents before and after the

addition of alpha-methyl-D-mannoside to the elution buffer
were collected and assayed for the human urokinase by
ELISA with specific monoclonal antibody to human
urokinase.

The results in Figure 14 show that human

urinary urokinase (purchased from American Diagnostica,
Inc.) contained a non-binding form of urokinase that was
eluted prior to the alpha-methyl-D-mannoside wash, and a
second peak eluted with alpha-methyl-D-mannoside buffer
which corresponds to a glycosylated urokinase.

The first

unglycosylated urokinase peak might be generated from the
urokinase from which carbohydrate moiety was degraded
during the protein purification procedures or storage.
The pSV2-uPA transf ected murine B16-Fl clones produced
only one human urokinase peak which was eluted with alphamethyl-D-mannoside and coincided with the glycosylated
urokinase peak observed in the human urokinase
preparation.

This result demonstrates that human

urokinase produced by the transf ected murine Bl6-Fl cells
is glycosylated.
Specific urokinase receptors have been described in
several cell lines (Vassalli gt al., 1985; Stoppelli et
al., 1985) and receptor binding has been shown to be
species specific (Huarte et al., 1987; Estreicher et al.,
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Figure 14.

concanavalin A affinity chromatography

of human urokinase from commercially purified
preparation (A) and from pSV2-uPA transfected Bl6-Fl
conditioned medium (B)
commercial human urokinase (A) or the serumfree conditioned medium collected from clone 7 of
pSV2-uPA transfected Bl6-Fl cells (B) was applied to
the Con A column.

The columns were washed with Tris

buffer and then same buffer containing alpha-methylD-mannoside (arrow).

Each fraction was collected

and assayed for human urokinase by the ELISA using
monoclonal antibody to human urokinase.
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1989).

Since human urokinase is produced by the

transfected murine cells, the ability of human urokinase
to bind to murine cell surf ace receptors was studied by a
competitive binding assay.

Cells were treated with mild

acid to unmask cell surface receptor sites and assayed for
the receptor binding with 125 I labeled human urokinase in
the presence of different concentrations of unlabeled
human urokinase.

The results (Figure 15) showed that the

human urokinase binds to a human cell line PC-3-Met
(Kozlowski et al., 1984), derived from a human prostate
carcinoma.

In contrast, the human urokinase showed no

specific affinity to the cell surface of the murine Bl6-Fl
cells.

This result demonstrates that the human urokinase

does not bind to the cell surface of murine Bl6-Fl cells.

Determination of Urokinase Activity
It was of interest to measure the increase in
plasminogen activator activity, due to the transfection of
pSV2-uPA, over the endogenous murine plasminogen activator
activity which is normally produced by Bl6-Fl cells.

The

activity was determined with a chromogenic substrate for
plasmin which is generated from plasminogen by the
urokinase secreted from the transfected cells.

Figure 16
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Figure 15.

Specific binding of human urokinase to

human PCJ-Met and murine B16-Fl cells
Binding of human urokinase (uPA) to the human
PC3-Met cell surface (0) and the murine B16-Fl cell
surface (0) was determined by receptor binding
assay.

Cells were treated with mild acid to unmask

the receptors on the cell surface.

PC3-Met and Bl6-

Fl cells were incubated with 125 1-labeled human
urokinase and different concentration of unlabeled
human urokinase.

Cells were washed with PBS/BSA and

lysed with detergent.
gamma-counter.

Lysed cells were counted in a

Nonspecific binding was determined

in the presence of excess (50 nM) unlabeled human
urokinase and subtracted from the each experimental
value.

Data are expressed as the mean of triplicate

determinations and standard deviations of the mean.
The human urokinase appears to specifically bind
only to the human PC3-Met cells, but not murine B16Fl cells.
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·Figure 16.

Secreted plasminogen activator activity

of Bl6-Fl and pSV2-uPA transfected Bl6-Fl cells as
determined against a chromogenic substrate
B16-Fl, B16-F10 or transfected B16-Fl cell
conditioned media were incubated with the plasmin
specific chromogenic substrate S-2251 (H-D-Val-LeuLys-p-nitroanilide) and DFP treated plasminogen.
After the incubation, the p-nitroaniline absorbance,
corresponding to substrate hydrolysis by plasmin
which was activated from plasminogen by urokinase
produced from conditioned media, was measured.
Nonspecific activity was measured in the absence of
cell conditioned media and subtracted from the
experimental value.

Plasminogen activator activity

was expressed in pg secreted to conditioned medium
per cell per hour.
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and Table 2 shows an increase in secreted plasminogen
activator activity of 3 to 4-fold in clones 7 and 10 over
cells transfected with pSV2-neo alone or untransfected
Bl6-Fl cells.

Three to four fold increase in clone 7 and

10 raises the plasminogen activator activity to the level
present in the more highly metastatic Bl6-Fl0 cell line.
The result also shows that transfection of pSV2-neo did
not affect urokinase production in Bl6-Fl cells.

Most of

cells used for the assay were passaged five to seven
times.
The results of the synthetic substrate assay were
confirmed by 125 I-fibrin assay for plasmin (Figure 17 and
Table 3).

In this assay, the plasminogen activator

activity was determined by measuring degradation of fibrin
those shown in Figure 16 and Table 2 were obtained by
125I-fibrin plate assay.
From the ELISA data of Table 1, two clones (clones
9 and 12) that produce the least amount of human urokinase
and two clones (clones 8 and 18) that produce the highest
amount of human urokinase (excluding clone 7 and 10) were
selected for further study.

The plasminogen activator

activity was determined with a chromogenic substrate for
plasmin for the clones 8, 9, 12, and 18 and compared to
that of clone 7 or pSV2-neo transfected Bl6-Fl cells.

The
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Table 2.

Quantification of secreted plasminogen activator

(PA) activity of Bl6-Fl, B16-F10, and transfected B16-Fl
cells by chromogenic substrate assaya

Cell

B16-Fl
B16-Fl (pSV2-neo)
Bl6-F10
Clone 7 (pSV2-uPA)
Clone 10 (pSV2-uPA)

Secreted PA activityb
(Mean ± SD)

3.90
4.42
11.9
13.1
12.1

+
±
±
±
+

0.36c,d
0.54c,e,f
1.06d
0.98e,g
2.29f ,g

acell conditioned media collected from B16-Fl, B16-FlO,
and B16-Fl transfected cells with pSV2-neo or pSV2-uPA
(clone 7 and clone 10) were incubated for 16 hours with
the plasmin specific chromogenic substrate S-2251 (H-DVal-Leu-Lys-p-ni troanilide) and DFP treated plasminogen.
After the incubation, the p-nitroaniline absorbance,
corresponding to substrate hydrolysis by plasmin, was
measured.
bPlasminogen activator activity is expressed in lxlo-2 pg
secreted to conditioned medium per cell per hour.
cNot significantly different (p = 0.11)
dsignificantly different (p = o.ooo)
esignificantly different (p = 0.000)
fsignificantly different (p = o.ooo)
gNot significantly different (p

=

0.25)
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Figure 17.

Secreted plasminogen activator activity

of Bl6-Fl and pSV2-uPA transfected B16-Fl cells as
determined by 125 1-fibrin plate assay
Conditioned media from Bl6-Fl, Bl6-Fl pSV2-neo
transfected, Bl6-Fl0, clone 7 and clone 10 of B16-Fi
pSV2-uPA transfected cells were incubated with DFPtreated plasminogen in 125 1-fibrin plate.

The

ability of plasmin, which was activated from
plasminogen by the urokinase produced from
conditioned media, was measured by the released
soluble 125 1-fibrin degradation product.
Nonspecific activity was measured in the absence of
cell conditioned media and subtracted from the
experimental value.

Plasminogen activator activity

was expressed in pg secreted to conditioned medium
per cell per hour.
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Table 3.

Quantification of secreted plasminogen activator

(PA) activity of B16-Fl, B16-F10, and transfected B16-Fl
cells as determined by 125 1-fibrin plate assaya

Cell

B16-Fl
B16-Fl (pSV2-neo)
B16-F10
Clone 7 (pSV2-uPA)
Clone 10 (pSV2-uPA)

Secreted PA activityb
(Mean ± SD)

4.02
4.81
11.6
11.7
10.8

±
±
±
±
±

0.24c,d
0.18c,e,f,
0.67d
0.45e,g
0.39f ,g

acell conditioned media collected from B16-Fl, B16-F10,
and B16-Fl transfected cells with pSV2-neo or pSV2-uPA
(clone 7 and clone 10) were incubated with DFP-treated
plasminogen in 125 1-fibrin plate. The ability of plasmin,
which was activated from plasminogen by the plasminogen
activator produced from conditioned media, was measured by
the released soluble 125 r-fibrin degradation product.
bPlasminogen activator activity is expressed in 1x10- 2 pg
secreted to conditioned medium per cell per hour.
cNot significantly different (p = 0.30)
dsignif icantly different (p = 0.000)
esignif icantly different (p = 0.000)
f significantly different (p = 0.000)
gNot significantly different (p = 0.52)

104
results in Table 4 show clones 8 and 18 secreted the same
amount of plasminogen activator activity as clone 7.
clones 9 and 12 also secreted the same amount of
plasminogen activator activity as pSV2-neo transfected
cells.

The difference in enzyme activity between clones 8

and 18 and clones 9 and 12 indicates that the increased
secretion of plasminogen activator activity of clones 7
and 10 is due to the human urokinase expression of the
transfected clones.
To test the stability of the urokinase gene
expression, the chromogenic assay was performed with the
to soluble peptides by plasmin which was activated from
plasminogen by the secreted urokinase.

Results similar to

conditioned medium collected from the C7 passaged more
than 20 times in cell culture.

The urokinase activity

from that particular sample was similar to those of early
passaged cells (data not shown).

In vivo Metastasis Assay
This assay assesses the effect of the secreted
human urokinase from Bl6-Fl pSV2-uPA transfected cells on
lung colonization, which measures tumor cell extravasation
from the blood and then growth into pulmonary tumors.
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Table 4.

Quantification of secreted plasminogen activator

(PA) activity of pSV2-uPA transfected B16-Fl cells (clones
1, 8, 9, 12 and 18) by chromogenic substrate assaya

Cell

Clone 7
Clone 8
Clone 9
Clone 12
Clone 18
B16-Fl
B16-Fl (pSV2-neo)

Secreted PA activityb
(Mean ± SD)
6.42
6.06
2.90
2.89
6.02
2.49
2.84

± 1 . 61 c,d,e,f
± 0.60c,d,e
+ 0.22g

±
±
±
±

0.24h
0.75c,d,f
0.59c
0.46g,h

acell conditioned media collected from 1 x 10 6 B16-Fl
transfected cells with pSV2-neo or pSV2-uPA (clone 7, 8,
9, 12 and 18) for 24 hours in 10 mm petri dishes were
incubated for 16 hours with the plasmin specific
chromogenic substrate S-2251 and DFP treated plasminogen.
After the incubation, the p-nitroaniline absorbance,
corresponding to substrate hydrolysis by plasmin, was
measured.
bPlasminogen activator activity is expressed in lxlo- 2 pg
secreted to conditioned medium per cell per hour.
cclones 7, 8, and 18 are different from B16-Fl at p
0.000.

=

dclones 7, 8, and 18 are different from B16-Fl (pSV2-neo)
at p = 0.000.
eNot significantly different (p = 0.35)
fNot significantly different (p = 0.41)
gsignif icantly different (p = 0.009)
hsignif icantly different (p = 0.015)
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C57BL/6 mice were tail vein injected with 100,000 tumor
cells from clones 7, clone 10, or control cells.

The

control cells transfected with pSV2-neo only, were made up
of a mixture of cells from randomly selected pSV2-neo
transfected clones, so as not to bias the controls in any
one direction.

Cells injected into the animal had been

passaged 4 to 5 times in cell culture following the
transfection.

Thirteen mice each, were used for each

control or experimental group, in every experiment.
Attention was given to the cell culture conditions, such
as confluency of the cells, and number of passages which
were kept identical for both control and experimental
cells in each experiment.

To assess the metastatic

potential of transfected cells, the number of lung tumors
which appeared on the lung surface were counted under the
dissecting microscope.

An earlier study compared the

results of microscopic examination of lung section to the
observation of lung surface tumors and found a close
correlation between the two results (Wexler, 1966).
Table 5 compares the number of metastatic tumors
formed in the lungs of C57BL/6 mice.

The pSV2-neo

transf ected cell mixture had a similar lung colonization
ability to that previously reported for untransfected Bl6Fl cells (Fidler, 1983).

Thus transfection alone does not
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Table 5.

Lung Colonization by B16-F1 Murine Melanoma

cells Transfected with Human Preprourokinase cDNA in a
SV40 Expression Vectora

Vector

Number of Tumors

Mean + S.E.

Experiment .l
pSV2-neo
(control)

1,1,2,3,3,3,4,4,4,4,9,
11,15

4.92 ± 1.16b

pSV2-neo &
pSV2-uPA
(Clone 7)

26,55,58,59,60,84,87,92,
99,102,112,137,172

87.9 + 10.7b

Experiment 2.
pSV2-neo
(control)

2,3,7,7,10,10,14,14,16,
21

10.5 + i . 88b

pSV2-neo &
pSV2-uPA
(Clone 10)

8,25,27,28,28,30,31,39,
45,58,59,96

39.5 ± 6.59b

aAnimals were injected i.v. in the tail vein with 100,000
B16-Fl transfected cells.

Mice were killed 17 days after

the injection and the number of lung metastatic foci was
counted.
bDifferent at p < 0.001 by both the Mann Whitney U-Test
(nonparametric rank sum test) and Student t-test.
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appear to significantly increase the metastatic potential
of the B16-Fl cells.

However, both clones 7 and 10, which

were selected for their high secretion of human urokinase,
showed a dramatic and significant (p < 0.001) increase in
lung colonization ability compared to controls.
To confirm our finding that the increased
plasminogen activator activity due to the production of
urokinase enhanced metastatic potential for clones 7 and
10, clones 8 and 12 were also tested for lung
colonization.

Clones 8 and 12 were selected for their

high and low secretion of human urokinase respectively
even though they were transfected with the same vectors,
pSV2-uPA and pSV2-neo.

The results in Table 6 compare the

number of metastatic tumors formed by clones 8 and 12.
Clone 8 showed a significant (p = 0.0019) increase in lung
colonization ability compared to clone 12.
Figure 18 shows typical lungs dissected from
control mice which were injected with pSV2-neo transfected
B16-Fl cells and experimental mice which received tumor
cells from clone 7.

Tumors from experimental mice are

shown to be mixture of amelanotic and melanotic while
tumors from control mice are mainly melanotic.

All tumors

from the control mice and experimental mice were divided
into melanotic or amelanotic groups and the number of
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Table 6.

Lung Colonization by B16-F1 cells transfected

with pSV2-uPA and pSV2-neo (clone 8 and 12)a

Number of Tumors

Vector

Mean ± S.E.

pSV2-neo &
pSV2-uPA
(clone 12)

12,34,46,74,94,98,101,
132,144,151

88.6 ± 14.9b

pSV2-neo &
pSV2-uPA
(Clone 8)

119,128,142,181,185,
>300,>300,>300

206.9 ± 28.5b

aAnimals were injected i.v. in the tail vein with 100,000
B16-Fl transfected cells.

Mice were killed 17 days after

the injection and the number of lung metastatic foci was
counted.
bDifferent at p

=

0.0019 by student t-test and p < 0.01 by

the Mann Whitney U-Test (nonparametric rank sum test).
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Figure 18.

Gross appearance of typical lungs

dissected from control (left) and experimental
(right) mice
Control mice were injected with 10 5 B16-Fl
cells transfected with pSV2-neo and experimental
mice received

io 5

clone 7 cells transfected with the

pSV2-neo and pSV2-uPA plasmids.
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tumors in each group were counted.

Table 7 shows the

percent of tumors in the two different color groups.

It

was observed that high urokinase secreting clones (clones
7, 10, and 8) produced predominantly amelanotic tumors
while pSV2-neo transf ected clones or low urokinase
secreting clone (clone 18) produced mainly melanotic
tumors.
Cytotoxicity assay was performed to test if murine
cells that produce human urokinase might generate any
immunologic response in C57BL/6 mice.

The 51 cr release

result shows no indication of immunological response
against the human urokinase produced by transf ected murine
cells (data not shown).

(Assay was carried out by the

clinical laboratory staff in Dr. John Clancy's lab.,
Department of Anatomy).
Spontaneous metastasis from foot pad tumor formed
by clone 7 cells was assayed to study the effect of
secreted urokinase on the full metastatic process.

Table

8 shows the number of pulmonary tumors formed in the
spontaneous metastasis experiment from primary tumors
grown in the hind leg foot pad of C57BL mice.

Clone 7

cells demonstrated an absolute ability to metastasize (all
experimental mice showed spontaneous metastasis), while
foot pad tumors produced by control Bl6-Fl pSV2-neo
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Table 7.

Color distribution of metastatic tumors in

murine lung from mice tail-vein injected with B16-Fl
transfected cellsa

Cells
Injected

Percentage of tumors in color category
Melanotic
Amelanotic
(Mean ± s . D. )

pSV2-neo
(control)

97.1 ± 6.98

2.91 ± 6.98

pSV2-neo &
pSV2-uPA (C7)

29.4 ± 6.85

70.6 ± 6.81

pSV2-neo
(control)

93.1 ± 8.57

6.46 ± 8.80

pSV2-neo &
pSV2-uPA (ClO)

37.7 + 8.79

62.5 ± 9.17

pSV2-neo &
pSV2-uPA (Cl2)

91.0 ± 4.84

9.83 + 4.86

pSV2-neo &
pSV2-uPA (CS)

7.66 ± 4.26

92.2 + 4.49

aColor of the lung tumors from control and experimental
groups were divided into two groups, melanotic and
amelanotic and tumor numbers were counted.

Results are

expressed in percent ± S.E. of tumor numbers in the
different color groups.
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Table 8.

Spontaneous pulmonary metastasis by B16-Fl

Murine Melanoma Cells Transfected with Human
Preprourokinase cDNA in a SV40 Expression Vectora

vector

number of colonies

mean ± S.E.

pSV2-neo
(control)

o,o,o,o,o,o,o,o,o,2,11

1.18 ± l.OOb

pSV2-neo +
pSV2-uPA
(Clone 7)

l,l,2,2,3,3,3,7,11,23,
26,33

9.58 ± 3.26b

aMice were injected subcutaneously into a footpad with
100,000 cells of transfected cells.
tumor-bearing foot was amputated.

Three weeks later,
Seven weeks after the

injection, animals were killed and the number of lung
metastatic foci were counted.
bDifferent at p < 0.001 by the Mann Whitney U-Test
(nonparametric rank sum test) and at p < 0.03 by the
Student t-test.
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transfected cells showed a low ability to spontaneously
metastasize (only 2 mice out of 11 showed pulmonary
tumors).

Demonstration of Human Urokinase Activity in Murine LYng
TUJ!!,ors
To determine the presence of human urokinase
produced by the pSV2-uPA transf ected cells in murine lung
metastatic tumors of clone 7, cells from the lung nodules
were plated in vitro and assayed for the human urokinase
by ELISA using monoclonal antibody.

The ELISA results in

Table 9 shows that clone 7 cells passaged through animal
secreted similar amount of human urokinase as the original
clone 7 cells.

The plasminogen activator activity from

both cells also was measured by chromogenic substrate
assay.

Table 10 shows that clone 7 cells, either primary

or passaged through animal, secreted similar amounts of
plasminogen activator activity.

Taken together, these

results indicate that the plasminogen activator activity
detected in the lung nodules is contributed by the human
urokinase from the pSV2-uPA transf ected cells and that the
phenotype of transfected cells was stable in vivo.
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Table 9.

Quantification of human urokinase production by

B16-Fl transf ected cells and the same cells passaged
through animal (PTA) by ELISAa

Cell

Bl6-Fl (pSV2-neo)
Bl6-Fl (pSV2-neo) PTAC
Bl6-Fl (pSV2-uPA) C7
Bl6-Fl (pSV2-uPA) C7 PTAc

Absorbance
(Mean±SD)
0.01
0.01
0.58
0.63

±
±
±
±

o.01b,d,f
o.01b,d,g
o.ose,f
0.06e,g

aThe secretion of urokinase from each colony was
quantitated by IMUCLONE uPA ELISA Kit (American
Diagnostica Inc.) on conditioned media taken from the
cells incubated in the serum free media for 40 hours.
bvalue equal to zero as no human urokinase is produced by
murine Bl6-Fl cells which was transfected with the
pSV2-neo plasmid.
cThe lung tumors removed from the mice which were injected
with the transfected cells were plated in vitro and
cultured for the assay.
dNot significantly different (p = 0.49)
eNot significantly different (p = 0.30)
f significantly different (p = 0.000)
gsignif icantly different (p = 0.000)
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Table 10.

Quantification of secreted plasminogen

activator (PA) activity of transfected cells and the cells
passaged through animal (PTA) by chromogenic substrate
assaya

Cell

Bl6-Fl (pSV2-neo)
Bl6-Fl (pSV2-neo) PTAC
Clone 7 (pSV2-uPA)
Clone 7 (pSV2-uPA) PTAC

Secreted PA activityb
(Mean ± SD)

2.49
2.84
6.42
6.71

±
±
±
±

o.6od,f
0.46d,g
i . 61 d,e,f
l.73d,e,g

acell conditioned media collected from 1 x 10 6 Bl6-Fl
pSV2-neo, Bl6-Fl pSV2-neo and pSV2-uPA (clone 7)
transfected cells, and the same cells passaged through
animal (PTA) for 24 hours in 10 mm petri dishes were
incubated for 16 hours with chromogenic substrate S-2251
and DFP treated plasminogen. After the incubation, the pnitroaniline absorbance, corresponding to substrate
hydrolysis by plasmin, was measured.
bPlasminogen activator activity is expressed in lxlo- 2 pg
secreted to conditioned medium per cell per hour.
cThe lung tumors removed from the mice which were injected
with the above cells were plated in vitro and cultured for
the assay.
dNot significantly different (p = 0.29)
eNot significantly different (p = 0.67)
f Not significantly different (p = 0.90)
gNot significantly different (p = 0.85)
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II. Inhibition of Urokinase Production in Murine B16-F10
Melanoma Cells and the Study of its Effect on Lung
colonization

Expression of Antisense Human Urokinase Gene
The plasmid pSV2-ASuPA containing 5' end of 265base-pair of preprourokinase sequence in an antisense
direction with respect to SV40 early gene promoter was
prepared from the the plasmid pSV2-dhfr and pRdzbuktt as
shown in Figure 7.

In the synthesis of pSV2-ASuPA, the

ligation on HindIII sites of pSV2-dhfr digest and 265
base-pair of human urokinase cDNA automatically brings the
pSV2-ASuPA in an antisense orientation.

The final pSV2-

ASuPA plasmid construction which is shown in Figure 8 was
confirmed by restriction endonuclease digestion map.
Murine Bl6-Fl0 melanoma cells of high metastatic
potential were similarly cotransfected with the plasmids
pSV2-ASuPA and pSV2-neo in 10:1 ratio, glycerol shocked,
and grown in the presence of Geneticin (G-418).

The

surviving colonies were assayed for the production of
urokinase by a filter immunoblot assay using a polyclonal
antibody to human urokinase as shown in Figure 19.

It has

been shown that polyclonal antibody to human urokinase
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Figure 19.

Filter i:mmunoblot analysis of

transf ected B16-F10 cell colonies
Bl6-Fl0 cells were transfected with pSV2-neo
(top) or cotransfected with pSV2-ASuPA and pSV2-neo
(bottom).

Transfected cells were cultured in MEM

supplemented with 10% heat inactivated FBS
containing Geneticin (G-418).

Five weeks later,

nitrocellulose membrane filters were placed over the
cell colonies to absorb urokinase being secreted.
The filters were treated with rabbit polyclonal
antibody to human urokinase followed by goat antirabbi t

IgG conjugated with alkaline phosphatase,

which were reacted with NBT/BCIP to give dark purple
color development corresponding to urokinase
presence.

Fifteen colonies that show light purple

color which indicates lower production of urokinase
were selected for further study.
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cross reacts with mouse urokinase (Ossowski, 19SS).
Fifteen colonies that demonstrated light purple color
indicating decreased amounts of urokinase secretion were
selected, transferred to separate petri dishes, and
expanded in MEM supplemented with 10% heat inactivated
FBS.

Determination of Urokinase Production
The secretion of urokinase activity into the cell
culture medium from the fifteen antisense colonies
selected by filter immunoblot assay were quantitated by a
chromogenic substrate assay following the activation of
plasminogen to plasmin.
clones

s,

Table 11 shows that antisense

10, 11, and 12 (ACS, AClO, ACll, and AC12)

secreted lower amounts of urokinase than other clones.
The secretion of urokinase activity of these four
antisense clones was confirmed by 125 r-f ibrin plate assay
as shown in Figure 20 and Table 12.

Of four antisense

clones, clone 10 (AClO) and clone S (ACS) secreted
approximately 70% of urokinase when compared to a mixed
population of B16-Fl0 or pSV2-neo transfected B16-F10
cells.
The incorporations of pSV2-ASuPA and pSV2-neo
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Table 11.

Quantification of secreted plasminogen

activator activity from B16-Fl0 transfected cells by
chromogenic substrate assaya

Clone No

Absorbance
(Mean ± SD)

Clone No

Absorbance
(Mean ± SD)

ACl
AC2
AC3
AC4

0.51
0.56
0.46
0.56

±
±
±
±

0.03
0.04
0.02
0.03

AC9
AClO
ACll
AC12

0.58
0.36
0.46
0.45

±
±
±
±

0.06
0.02
0.03
0.02

AC5
AC6
AC7
ACS

0.49
0.70
0.47
0.40

±
±
±
±

0.01
0.04
0.02
0.03

AC13
AC14
AC15

0.68
0.61
0.59

±
±
±

0.04
0.03
0.02

0.52

±

0.03

Bl6-Fl0

0.51 + 0.02

Bl6-Fl0Neo

aB16-FlO or transfected Bl6-Fl0 cell conditioned media
were incubated for 16 hours with the plasmin specific
chromogenic substrate S-2251 (H-D-Val-Leu-Lys-pnitroanilide) and DFP treated plasminogen.

After the

incubation, the p-nitroaniline absorbance, corresponding
to substrate hydrolysis by plasmin, was measured.
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Figure 20.

Secreted plasminogen activator activity

of B16-F10 and pSV2-ASuPA transf ected B16-F1 cells
determined by 125 1-fibrin plate assay
Conditioned media from Bl6-Fl0, 816-FlO
transfected with pSV2-neo, antisense clones 8 (ACS),
10 (AClO), 11 (ACll), and 12 (AC12) of transfected
with pSV2-ASuPA were incubated with DFP-treated
plasminogen in 125 r-fibrin plate.

The activity of

plasmin, which was activated from plasminogen by the
urokinase produced from conditioned media, was
measured by the released soluble 125 r-f ibrin
degradation product.

Nonspecific activity was

measured in the absence of cell conditioned media
and subtracted from the experimental value.
Plasminogen activator activity was expressed in pg
secreted to conditioned medium per cell per hour.
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Table 12.

Quantification of secreted plasminogen

activator (PA) activity of Bl6-Fl0 and transfected Bl6-F10
cells as determined by 125 I-fibrin plate assaya

Cell

B16-Fl0
B16-F10 (pSV2-neo)
ACS (pSV2-ASuPA)
AClO (pSV2-ASuPA)
ACll (pSV2-ASuPA)
AC12 (pSV2-ASuPA)

Secreted PA activityb
(Mean ± SD)

12.0
11.9
8.33
8.71
9.34
9.60

±
±
±
±
±
±

0.37e
0.83e
0.59c,d
0.71c,d
0.46c,d
0.37c,d

acell conditioned media collected from B16-F10 and pSV2neo or pSV2-ASuPA transfected B16-Fl0 cells were incubated
with DFP-treated plasminogen in 125 r-fibrin plate. The
ability of plasmin, which was activated from plasminogen
by the plasminogen activator produced from conditioned
media, was measured by the released soluble 125 r-fibrin
degradation product.
bPlasminogen activator activity is expressed in 1x10- 2 pg
secreted to conditioned medium per cell per hour.
cAC8, AClO, ACll, and AC12 are significantly different
from B16-F10 at p = 0.008, 0.0022, 0.0016, and 0.0014
respectively.
dAcs, AClO, ACll, and AC12 are significantly different
from B16-F10 (pSV2-neo) at p = 0.0037, 0.0031, 0.0095, and
0.0012 respectively.
eNot significantly different (p

=

0.95)
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plasmids into the Bl6-Fl0 cell genomic DNA of antisense
clones 10 and 8 were assayed by Southern blot
hybridization assay as shown in Figure 21.

The DNAs were

prepared from the antisense clones 10 and 8 and pSV2-neo
transfected cells.

To detect the pSV2-neo and pSV2-ASuPA

incorporation, DNAs were digested with PstI, separated by
electrophoresis, transferred to nitrocellulose filter, and
probed with 32 P-labeled HpaI-PstI pSV2-ASuPA fragment.
The digestion of pSV2-ASuPA with PstHI generates four DNA
bands with base pairs of 2418, 1430, 958, and 923 pairs
and 32 P-labeled probe hybridizes with all the band.

The

digestion of pSV2-neo with PstI generates two DNA bands
with base pairs of 3540 and 958 and the probe hybridizes
with both bands.

Figure 21 shows that antisense clones

AClO and ACS demonstrate the restriction endonuclease
digested bands identical to those of pSV2-ASuPA plasmid.
The densitomer scan of autoradiograghs (data not shown)
suggests less than 5 copy numbers of pSV2-ASuPA were
present in the transfected antisense clones 10 or 8 cells.

Lung Colonization Assay
To assess the effect of inhibition of urokinase
production on lung colonization, antisense clones 10 and 8

127

Figure 21.

Southern blot hybridization analysis of

DNA i&olated from antisense clones 10 (AC10) and 8
(AC8) of pSV2-ASuPA transfected cells, B16-F10, and
B16-F10 pSV2-neo transfected cells
DNAs were isolated from antisense clone 10
(AClO) and S (ACS) of pSV2-ASuPA transfected B16-F10
cells, pSV2-neo transfected cells, or untransfected
Bl6-Fl0 cells.

The DNAs (10 ug) were cleaved with

PstI and electrophoresed through O.S% agarose gel.
A control pSV2-ASuPA plasmid preparation was
similarly digested with PstI and different amounts
were loaded onto the same gel.

The DNAs were

transferred to nitrocellulose and probed with 32 Plabeled HpaI-PstI fragment of pSV2-ASuPA.

Lanes 1

and 2 contain DNA made from 7 x 10 6 , and 3.5 x 10 6
cells AClO.

Lanes 3 and 4 contain DNA made from 7 x

10 6 and 3.5 x 10 6 cells of ACS.

Lane 5 contain DNAs

made from 7 x 10 6 cells of untransf ected Bl6-Fl0 and
lane 6 from 3.5 x 10 6 of pSV2-neo transfected cells.
Lanes 7,

s, and 9 contain pSV2-ASuPA DNA of 10, 5, 2

ng respectively.
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were injected to mice through tail vein.

Table 13 shows

the results of the lung colonization assay of antisense
clones 10 and 8.

AClO and ACS cells which produced

approximately 70% of urokinase compared to Bl6-Fl0 cells
showed a 40 to 42% decrease in the ability to form lung
tumors (p = 0.0016 and 0.0019 respectively by Student's t
test and p < 0.005 and p < 0.005 by the Mann Whitney
test respectively.

u-

The pSV2-neo transfected Bl6-Fl0 cell

mixture showed a similar lung colonization ability
compared to untransfected Bl6-Fl0 cells (Fidler, 1983).
Thus, as shown in Bl6-Fl cell transfection, transfection
alone does not affect metastatic potential of the Bl6-Fl0
cells.
Figure 22 shows the gross appearance of typical
lungs dissected from control mice (injected with pSV2-neo
transfected cells) and experimental mice (injected with
pSV2-neo and pSV2-ASuPA transfected cells).

It was

observed the majority of tumors from the control mice were
smaller than that from the experimental mice.

Thus, all

the tumors from the control and experimental mice were
grouped into three different sizes (small, medium, and
large) and number of tumors in each size category were
counted.

Small size tumor indicates less than 0.2 mm,

medium size between 0.2 mm and 0.7 mm, and large size more
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Table 13.

Lung colonization by B16-F10 murine melanoma

cells transfected with human preprourokinase antisense
gene in a SV40 expression vectora

Vector

Number of Tumors

Mean ± S.E.

Experiment .l
pSV2-neo
(control)

32,34,55,56,71,76,80,90
91,92,97,99

72.8 + 6.8b

pSV2-neo &
pSV2-ASuPA
(AClO)

27,28,28,29,33,34,37,40,
45,45,60,67,86

43.0 ± 4.9b

Experiment 2pSV2-neo
(control)

116,136,148,155,189,
192,245,254,275,306,321

212.5 ± 21.5C

pSV2-neo &
pSV2-ASuPA
(AC8)

51,71,73,101,126,135,
150,152,156,166,173

123.1 ± 12.8c

aAnimals were tail vein injected with 1x10 5 B16-Fl0
transfected cells.

Mice were killed 17 days later and

number of lung metastatic foci was counted.
bDifferent at p = 0.0016 by Student t-test and p < 0.01
by the Mann Whitney U-test (nonparametric rank sum test).
cDifferent at p = 0.0019 by Student t-test and p < 0.01
by the Mann Whitney U-test.
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Figure 22.

Gross appearance of typical lungs

dissected from control (left) and experimental
(right) mice
Control mice were injected with 10 5 Bl6-Fl0
cells transfected with pSV2-neo and experimental
mice received 10 5 antisense clone 10 (AClO) cells
transfected with the pSV2-neo and pSV2-ASuPA
plasmids.
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than 0.7 mm in diameter.

Figure 23 and Table 14 shows the

size of metastatic tumors in lungs expressed in percent of
tumor numbers in the different size categories.

It was

observed that more than 60% of tumors produced by
experimental mice belong to large size category, while
Bl6-Fl0 pSV2-neo transf ected cells produce mainly small
and medium size tumors.
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Figure 23.

Size of metastatic tumors in murine lung

from mice tail-vein injected with B16-Fl0
transf ected cells
Size of the lung tumors from control and
experimental mice were determined and divided into
three categories, small (<0.2 mm in diameter),
medium (0.2 mm-0.7 mm), and large (>0.7 mm).
Results are expressed in percent of tumor numbers in
the different size category.
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Table 14.

Size of metastatic tumors in murine lung from

mice tail-vein injected with B16-F10 transfected cellsa

Cells
Injected

Percentage of tumors in size category
Small
Medium
Large
(Mean± S.E.)

pSV2-neo
(control)

32.8 ± 2.86

48.2 ± 2.37

21.2 ± 2.75

pSV2-neo &
pSV2-ASuPA
(AClO)

13.9 ± 1.81

25.2 ± 2.07

60.1 ± 3.16

pSV2-neo
(control)

37.0 + 1.86

47.0 ± 2.49

16.l ± 2.70

pSV2-neo &
pSV2-ASuPA
(ACS)

11.2 + 2.27

24.1 ± 2.14

64.7 ± 3.42

asize of the lung tumors from control and experimental
groups were measured and divided into three size
categories, small (<0.2 mm in diameter), medium (0.2 mm0.7 mm), and large (>0.7 mm).

Results are expressed in

percent ± S.E. of tumor numbers in the different size
category.

CHAPTER V

DISCUSSION
We have shown in this work direct evidence for the
importance of urokinase in tumor cell metastasis by
modifying the gene expression in murine B16 melanoma tumor
cells.

The metastatic potential of the cells transfected

with preprourokinase cDNA was dramatically enhanced
compared to the control cells in vivo.

In addition, the

cells transfected with antisense cDNA of urokinase gene
showed decreased metastatic potential in vivo.

Cell Lines Selected for the Study
B16 melanoma cell lines, B16-Fl and B16-F10, which
metastasize to form pulmonary tumor nodules (Fidler, 1973)
were used in this study.

The B16 tumor lines have been

established by Fidler (1973) by injecting tumor cells i.v.
into syngeneic C57BL/6 mice, isolating, and then culturing
the secondary lung tumor nodules in tissue culture.

The

B16-Fl cell line was passaged once through the selection
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process, while Bl6-Fl0 cell line was passaged ten times.
The Bl6-Fl cell line possesses low ability to form
metastatic lung colonies, while the Bl6-Fl0 cell line
shows high ability when injected i.v. into syngeneic
C57BL/6 mice (Fidler, 1975).

These cell lines have been

used by a number of investigators to determine a
quantitative correlation between the production of
plasminogen activator and their capacity to metastasize.
Wang et al.

(1980) reported quantitative differences in

plasminogen activator production between low metastatic
Bl6-Fl and high metastatic Bl6-Fl0 melanoma sublines, the
latter producing more plasminogen activator activity than
the Bl6-Fl cells.

Nicolson et al.

(1976) however showed

contradictory results, reporting a lack of correlation in
plasminogen activator activities between variant Bl6
sublines such as Bl6-Fl, Bl6-F5, Bl6-Fl0, and Bl6-Fl3.

Expression of Human Urokinase Gene in 816-Fl Melanoma
Cells
The DNA-mediated transfection technique (Graham and
van der Ed, 1973) was used as a means of introducing
foreign genes into the murine melanoma cells.

The optimal

transfection conditions as described in the Methods
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section were developed specifically for B16 cell lines.
The human preprourokinase gene was successfully expressed
in B16-Fl cells under the control of an SV40 early gene
promoter (pSV2 vector).

The expression of the

incorporated preprourokinase gene was found to be stable.
No loss of human prourokinase expression was observed even
after over 20 passages of the transfected cells.
The data in Figure 16 and 17 show that clone 7 and
clone 10 of pSV2-uPA transfected cells secrete a three to
four fold increase in plasminogen activator activity.

The

enhanced plasminogen activator activity in clone 7 and
clone 10 was shown to be specifically related to human
urokinase and not to the endogenous murine urokinase based
on the following observations: (i) The clones were
initially selected based soly on their high production of
human urokinase, by a filter immunoblot assay using a
polyclonal antibody to human urokinase (Figure 9), (ii) In
a second selection, from those clones selected by the
filter immunoblot assay, clones 7 and 10 were shown to
produce the highest level of human urokinase by ELISA
using a monoclonal antibody to human urokinase (Table 1).
Further characterization of the selected cells showed: (i)
Urokinase produced by clone 7 was glycosylated as expected
for the human urokinase (Figure 16).

The murine urokinase
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is not a glycoprotein (Belin, et al., 1985), (ii) Southern
blot hybridization analysis (Figure 10) demonstrated that
multiple copies of the human urokinase gene were
incorporated in the genomic DNA of clone 7.

The human

urokinase was selectively identified under the blotting
conditions used for the assay.

The murine urokinase gene

did not hybridize with the human cDNA probe under the
conditions used, and, (iii) Northern blot hybridization
analysis (Figure 5) demonstrated human urokinase gene
expressions by clone 7 and clone 10.

Glycosylation of Human Urokinase .by Murine Cells
The result of concanavalin A affinity
chromatography (Figure 14) demonstrates that the human
urokinase, produced by the transfected murine Bl6-Fl
cells, is glycosylated.

The murine urokinase gene lacks a

glycosylation site (Belin et al., 1985) and is therefore
not a glycoprotein.

It is not surprising that the human

gene product would be glycosylated since human urokinase
contains a glycosylation site in its amino acid sequence
(Holmes et al., 1985; Ricco et al., 1985).

A carbohydrate

side chain, containing at least four glucosamine and two
galactosame residues, was reported at asparagine in

141
position 144 of the human urokinase B chain (Steffens et
al., 1982).

Lack of Binding of Human Urokinase to Murine Receptor
As depicted in Figure 15, human urokinase does not
bind to cell surface receptor sites on the murine B16-Fl
cells.

It is not known whether the lack of binding is the

result of the glycosylation of human urokinase, or due to
the other changes in the structure of the urokinase that
prevents the human urokinase from binding to the mouse
receptors.

The observation that human urokinase does not

bind to murine cell receptors is in agreement with other
studies that reported a lack of cross-species binding of
urokinase to cell surface receptors.

Huate et al. (1987)

reported no significant binding of human prourokinase to
mouse spermatozoa.

Most recently, Estreicher et al.

(1989) demonstrated that human, mouse, and porcine
urokinase bind to the corresponding cell receptors of the
same species, while human urokinase failed to bind to
murine MSV-3T3 cells and murine urokinase did not bind to
human HeLa cells.

Experimental Model for in vivo Metastasis Assay
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To assay the metastatic potential of the
transf ected Bl6-Fl cells expressing the human urokinase
gene in vivo, the lung colonization and spontaneous
metastasis assays were employed.

In the lung colonization

assay, mice were i.v. injected through the tail vein, and
2-3 weeks later the animals were sacrificed and tumor
nodules on the lung surface were counted under a
dissecting microscope (Fidler, 1975).

This assay measures

tumor cell extravasation from the blood stream, invasion
of basement membrane and extracellular matrix, and then
growth into pulmonary tumors.

In the spontaneous

metastasis model, tumor cells injected in the foot pad of
the mouse, grow into a primary tumor site and metastasize
as secondary tumors to the lung (Fidler, 1978).

This

assay tests the full metastatic process in which the tumor
cells intravasate through the capillary endothelial walls,
survive in the circulation, extravasate from the
capillaries through the basement membrane, and invade the
extracellular matrix to establish a new tumor site.

The Effect of Increased Expression of Urokinase on Lung
Colonization Potentials
Three of the clones (clones 7, 8, and 10) among the
human preprourokinase transfected Bl6-Fl cells, were
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chosen for in vivo metastatic assay.

All of them showed a

dramatic increase in lung colonization following tail vein
inoculation (Table 5 and 6).

The ELISA and chromogenic

substrate assays for plasminogen activator confirmed the
human urokinase activity in the cells from the lung
nodules (Table 9 and 10).

These results clearly show that

the increased lung colonization potential of the clones 7,
8, and 10 is due to the human urokinase produced by the
pSV2-uPA transfected cells.

Since the cells were solely

selected for their ability to secrete human urokinase
which does not bind to cell surface receptors, the issue
of whether urokinase acts to promote metastasis on the
cell surface or at locations away from the surf ace can be
addressed.

Our results demonstrate that the increased

secretion of human urokinase activity strongly promotes
metastasis in vivo.

These results are in agreement with

those recently reported by Cajot §..t. al. {1989).

These

authors transf ected the human urokinase gene into mouse L
cells and showed a correlation between the modulation of
prourokinase gene expression and the degradation of
extracellular matrix by in vitro invasion through a
basement membrane like material, Matrigel.

Their results

demonstrated that urokinase binding to the cell surf ace is
not required for the increased degradation and invasion of
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the extracellular matrix.

These authors did not assay

their cells in an in vivo model for metastasis.

Axelrod

et al. (1989} also recently demonstrated that their ras
transformed murine NIH3T3 cells, transfected with
recombinant human urokinase, produced 30-fold elevation in
urokinase activity and manifested an increased invasion
rate in an in vitro basement membrane assay.

They also

showed that the transfected cells had a sixfold increase
in pulmonary metastatic lesions after i.v. injection into
nude mice.
Other authors however support the hypothesis that
cell surface-localized urokinase activity is critical for
tumor cell metastasis.

Ossowski (1988} demonstrated that

a saturation of human tumor cell, HeLa, receptors with
exogenous human urokinase enhanced the invasion of the
chick embryo chorioallantoic membrane.

This suggests that

urokinase binding to its receptor is important for the
increased invasive potential of the tumor cells.

A recent

study by Hearing et al. (1988) demonstrated the presence
of urokinase activity on the cell surface of B16 melanoma
cells by immunofluorescence.

The authors also reported

that the preincubation of these cells expressing urokinase
with an antibody to urokinase caused a reduction in their
lung colonization ability when injected through the tail
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vein of mice.

Based on these data, the authors argued

that cell surface localized urokinase activity has a
critical role in lung colonization.

However, the

statistical significance of their data does not appear
conclusive.

In Table 2 of their report, they tested the

effect of urokinase specific antibodies on pretreated Bl6
cells in 12 separate experiments.

Out of 12 experiments,

the authors reported that three experiments showed no
significant difference between the two groups using
student t test at p

~

0.05.

However, by a Wilcoxon non-

parametric analysis of their experimental data, only two
of the twelve experiments with anti-urokinase pretreated
cells showed a significant decrease (at p
colonization as compared to the controls.

~

0.05) in lung
In our study,

we show that the human urokinase does not bind to the
murine cell surface receptor, yet it clearly promotes
metastasis.
The role of the cell surf ace urokinase receptors
may serve to focus the enzyme activity at critical sites
on the cell surface.

The binding of urokinase to its

receptor, however, may also serve different functions than
to promote metastasis.

For example, it has been suggested

that urokinase may bind to cells and act as a cell mitogen
to induce cell proliferation (Kirchheimer et gl., 1987;
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Takada and Takada, 1989; Kirchheimer et al., 1989).
Regardless of the role of the cell surf ace associated
urokinase, the results in this report show that an
increase in the unbound, secreted form of human urokinase
dramatically increased spontaneous metastasis and lung
colonization by the Bl6-Fl cells.

Future investigation

that would help define the role of the urokinase receptor
may involve cloning the urokinase receptor gene and its
subsequent transfection into Bl6 cells.

Such study would

help elucidate the effect of urokinase cell surface
receptor binding in invasion and metastasis in vivo.
The lung colonization data of the clones 7, 8, and 10 in
Table 5 and 6 and increased urokinase secretion of these
clones infer that the increase in lung colonization by
Bl6-Fl cells is directly related to an increased urokinase
activity.

A comparison of the plasminogen activator

activity of Bl6-Fl cells, Bl6-Fl pSV2-uPA transfected
cells (clone 7 and clone 10), and Bl6-Fl0 cells show that
the clone 7 cells produce plasminogen activator activity
equal to that of the Bl6-Fl0 cells (Table 2 and 3).

In

addition, the lung colonization potential for Bl6-Fl0
cells is similar to that observed for the clone 7 cells
(Schultz et al., 1988).
A positive correlation between production of
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plasminogen activator and a spontaneous metastatic
potential for Bl6-Fl and Bl6-Fl0 cells has been previously
reported (Wang et al., 1980).

This earlier report,

however, while showing a correlative increase in
plasminogen activator production with increased
spontaneous metastasis, was not based on a known increase
in the expression of a single specific gene.

Multiple

differences have been reported between Bl6-Fl and Bl6-Fl0
cells besides the differences in urokinase production.
For example, there are differences in membrane lipid
composition (Schroeder and Gardiner, 1984), in the
expression of a 72 Kd glycosylated protein by Bl6-Fl0
cells and not by Bl6-Fl (Kimura and Xiang, 1986), and in
response of lung colonization to the monoclonal antibodies
produced to tumor-associated antigens of Bl6-Fl or Bl6-Fl0
cells (Herd, 1987).

In addition, Bl6-Fl0 cells showed an

increased glycosyltransferase activity as compared to Bl6Fl counterparts (Bosmann et .9..1.., 1974) and Bl6-Fl0 cells
have a greater propensity to form in vitro aggregates with
artificially disaggregated lung cells than Bl6-Fl cells
(Nicolson and Winkelhake, 1975).
The selection of the clones in this study was based
solely on the ability of transfected cells to produce
secreted human urokinase.

The secreted human urokinase in
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the B16-Fl cell line is shown to raise the metastatic
potential of B16-Fl cells to that of B16-F10.

This

finding supports the conclusion that increase in urokinase
activity is sufficient to explain the difference in
metastatic potential between B16-F10 and Bl6-Fl cells.
Blood-borne metastasis is a multiple step process
which may be subdivided into several steps: (i) detachment
of malignant tumor cells from the original tumor mass,
(ii) invasion through the extracellular matrix and
basement membrane with intravasation through the capillary
endothelial walls, (iii) travel of tumor cells through the
circulation, (iv) arrest in the capillary beds of the
target tissue,

(v) extravasation from the capillaries

through the basement membrane and extracellular matrix,
and (vi) implantation and growth of secondary tumor cells
at a new site.

The most critical steps in the metastatic

process, where proteolytic enzymes have a role, appears to
be the intravasation and extravasation steps (Liotta et
al., 1982).
The hypothesis that urokinase plays an important
role in intravasation comes from the earlier work of
Ossowski and Reich (1983) who showed that an antibody to
human urokinase only inhibited lung colonization in the
chick embryo when human tumor cells were placed on the
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chorioallantoic membrane.

Ossowski (1988) later reported

in this model, a lack of urokinase effect on the
extravasation step of metastasis by showing that the
urokinase antibody did not inhibit metastasis when human
tumor cells were directly injected into a chick embryo
vein, as opposed to the cells being placed on the
chorioallantoic membrane.

These experiments support the

argument that urokinase is important in the intravasation
step, but not in the extravasation step.
The argument of Ossowski agrees with the current
interpretation of the role of fibrin in metastasis.

It

has been argued that coagulation and the formation of
microthrombi might promote the attachment of tumor cells
to the capillary walls of the target organ, forming a
stationary phase of tumor cells which allows time for the
extravasation of tumor cells to occur (Dano et al., 1985;
Markus et al., 1984; Harvey et al., 1988).

Urokinase,

which can promote fibrin degradation through plasmin
mediated fibrinolysis, would act against the formation of
this protective stationary phase.

Subsequently high

urokinase activity in the extravasation step should lead
to a decrease in lung colonization (Markus et al., 1984).
In fact, Markus et al. (1983) compared the secretion of
urokinase between the primary and metastatic tumors of
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different types and found that urokinase secretion by
metastatic tumors were lower than those of primary tumors.
Harvey et al. (1988) also made similar observations which
led to the proposal that reduced secretion of urokinase of
metastatic tumors might provide a distinct advantage to
tumor cells destined to initiate metastatic foci, and may
contribute to the ability of circulating cancer cells to
lodge in the blood vessels of the target organs.

This

hypothesis is also supported by the study of Gunji and
Gorelik (1988) who demonstrated that the presence of
fibrin deposition on tumor cells protected them from
immunological destruction.

However, this hypothesis does

not agree with other reports.

Iwakawa et al. (1986)

demonstrated that an anticoagulant, which suppresses
coagulation via inhibition of thrombin (which activates
fibrinogen to fibrin) increased, rather than decreased,
the number of lung colonies after i.v. injection of tumor
cells.

Ostrowski et al. (1986) reported similar findings

that, mice implanted with mini-isopump infusion of a
thrombin inhibitor produced increased B16 melanoma lung
colonization.
The results of the lung colonization assay (Table 5
and 6) in this study, clearly shows an increase in
urokinase activity by the C7, ClO, and C8 clones of the
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pSV2-uPA transf ected cells which caused a dramatic
increase in lung colonization ability.

The lung

colonization assay by tail vein injection (Table 5 and 6)
measures the extravasation step of the metastatic process,
as the tumor cells are directly injected into the blood,
circumventing the earlier steps of the metastatic process.
our conclusion that urokinase is important in the
extravasation step of metastasis is consistent with the
recent similar observations by Axelrod et al. (1989), that
H-ras-transformed NIH3T3 cells expressing high levels of
urokinase activity were more efficient in lung that
increased plasminogen activator activity in rat mammary
adenocarcinoma cells correlated with their lung
colonization ability.
The increase in secreted urokinase activity also
provided the clone 7 cells with an ability to
spontaneously metastasize from a primary tumor in the foot
pad (Table 8).

The spontaneous metastasis assay measures

the ability of tumor cells to intravasate through the
capillary endothelial walls, survive in the circulation,
extravasate from the capillaries through the basement
membrane, and invade the extracellular matrix to establish
a new tumor site.

These results are in agreement with

earlier work by Wang et al. (1980) who demonstrated that
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high plasminogen activator production by B16-Fl0 subline
cells contributed to spontaneous metastasis, whereas B16Fl cells of low plasminogen activator production, had
decreased pulmonary metastases.
The increased spontaneous metastatic ability of
clone 7 (Table 8) might be due to (i) the increase in the
ability of the clone 7 cells to extravasate, as shown by
the colonization assay (Table 5), (ii) the acquisition of
colonization.

Another report that support this hypothesis

is the earlier study by Carlsen et al. (1984) which showed
an increased ability to intravasate, or (iii) the increase
in ability for both intravasation and extravasation.

If

urokinase activity was essential only in the extravasation
step, then the ability of clone 7 to spontaneously
metastasize may be simply due to the increased ability to
extravasate.

Whether the secreted form of urokinase

activity is controlling the intravasation as well as the
extravasation steps in the metastatic process remains to
be clarified.

Models that specifically isolate the

intravasation step need to be developed in order to
determine precisely how urokinase affects this step in the
metastatic process.
The cells secreting lower amounts of human
urokinase (pSV2-neo transfected B16-Fl or C12 of pSV2-neo
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and pSV2-uPA transfected cells) produce predominantly
melanotic tumors as shown in Table 7.

In contrast, the

lung nodules formed by the cells secreting higher amounts
of human urokinase consist of mixtures of amelanotic and
melanotic tumors.

In all three clones (clones 7, 10, and

8) the lesions predominantly demonstrated the amelanotic
phenotype.
Phenotypic change cannot be attributed to the pSV2neo transfection since all the clones contain the pSV2-neo
gene.

The overproduction of urokinase may be responsible

for the expression of this phenotype since the only
difference between these groups is the amount of human
urokinase secretion.

Therefore high amounts of urokinase

secretion in B16-Fl cells might inhibited melanin
synthesis/production.

The absence of the pigment in

amelanotic tumor is reported to be the result of
deficiency of tyrosinase activity (Slominski et al., 1987;
Bennett et gl., 1986) even though some investigators
reported that tyrosine activity did not correlate in vitro
with melanin synthesis in K1735 SW-1 cells (Price et al.,
1988).
A possible link between the high urokinase
production and the metastatic potential may be the state
of differentiation of the B16 cells.

It has been
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argued that more malignant cells are less differentiated
(Bennett et al., 1986).

In the B16 melanoma cell lines,

melanin formation may correlated with differentiation.
Thus amelanotic cells are less differentiated and also
more metastatic.

Urokinase production may affect the

metastatic potential of a cell by changing its state of
differentiation.

However B16-F10 cells secrete a similar

amount of urokinase as C7 cells but produce melanotic lung
nodules.
Several reports have linked melanin synthesis with
a reduction in tumor cell proliferation
1964; Lotan and Lotan, 1980).

(Gray~

al.,

Other investigators have

also suggested a positive correlation between tumor cell
malignancy and the amelanotic phenotype in B16 cell lines
(Romsdahl and Hsu, 1972; Lotan and Lotan, 1980).

Our

study confirmed these reports by showing that transfected
cells secreting human urokinase undergo a phenotypic shift
to cells that are more metastatic and form amelanotic
colonies.

The Effect of Inhibition of Urokinase Production in the
Lung Colonization Potential
If urokinase is required for tumor cell
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colonization (Table 5 and 6), then the inhibition of
urokinase activity should lead to a reduction in
metastasis.

By transfection of B16-F10 cells with an

antisense urokinase gene, it may be possible to evaluate
the effects of inhibiting urokinase gene expression on the
metastatic process.

B16-F10 melanoma cells of high

metastatic potential were transfected with a plasmid
containing human urokinase in the antisense direction
(pSV2-ASuPA).

The antisense clones 10 (AClO) and 8 (AC8)

cells which produced 30% less urokinase activity were
selected (Table 11, 12 and Figure 20).

A Southern blot

hybridization assay showed the incorporation of the
antisense plasmid into the genomic DNA of these cells
(Figure 21).

Tail vein injection by these two clones

showed a 40% reduction in lung colonization (Table 13).
These results are in agreement with our previous
experiments in which pSV2-uPA transf ected clones of Bl6-Fl
cells showed increased urokinase production and increased
lung colonization.

Taken together these two results give

supporting evidence that urokinase has an essential role
in extravasation process of lung colonization by B16
melanoma cells.

This is in contrast to the results

reported in the chorioallantoic membrane experiment which
concluded that urokinase does not play a role in the
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extravasation step (See previous discussion, Ossowski and
Reich, 1983).
The human urokinase gene transf ected C7 clone
showed that approximately 150 copies of the urokinase gene
was incorporated in Bl6-Fl cell DNA genome.

After

transfection of the antisense gene (pSV2-ASuPA) with the
same SV40 expression vector, a small copy number of
antisense urokinase genes were shown to be incorporated in
the Bl6-Fl0 genomic DNA in the most inhibited cell colony.
The difficulty of observing high copy number for
incorporation of the antisense gene might be explained by
the necessity of urokinase expression for cell viability.
Cells with higher copies of incorporated antisense
urokinase gene might fail to survive, hence escape
detection.

It has been proposed that urokinase is a

growth stimulant in various cell lines by several
investigators (Kirchheimer et al., 1987; Kirchheimer et
al., 1989; Tanaka and Tanaka, 1989).

Earlier study showed

the production of plasminogen activator reached maximum
during the logarithmic growth of transformed 3T3 cells and
decreased as the cells reach the confluence (Jaken and
Black, 1979).

It was also shown that the production of

urokinase correlated with the proliferative state of the
melanoma cells (Grimmaldi et al., 1986).
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An attempt to demonstrate antisense mRNA expression
by Northern blot hybridization was made.

However, it was

not possible to detect the antisense transcript in the
pSV2-ASuPA transf ected cells because of low abundance of
antisense mRNAs.

A more sensitive assay to demonstrate

the presence of the antisense transcript would be to use
the polymerase chain reaction (PCR) amplification,
following reverse transcriptase treatment, to convert mRNA
to cDNA (Saiki et al., 1988).
The variation in the numbers of lung colonies
between the control groups in Experiment 1 and 2 did not
closely coincide, as is shown in Table 13.

This may be

the result of the use of different lots of animals or the
use of cells from different time period.

Since the

control group was always tested in identical manner to the
experimental group for each experiment, the important
consideration for interpreting the data is the relative
number of metastases for both control and experimental
animals in any one set of experiments carried out at the
same time and with the same lot of cells and animals.

The

variation in average numbers of lung colonies in each of
the two separate experiments carried out at different time
periods should not affect the conclusions of this work.
Table 14 and Figure 22 and 23 show that the
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metastatic lung tumors from the mice injected with
antisense clones 10 or 8 were larger than those in control
mice containing cells transfected with the pSV2-neo
plasmid alone.

This result suggests that decreased

urokinase production inhibits metastasis but not the
growth of tumors.
Future studies to assess the role of urokinase in
metastasis would be to regulate urokinase activity by
means of plasminogen activator inhibitors (PAis).

Several

workers have shown that there are at least three
immunologically distinct PAis, including PAI-1, PAI-2, and
protease nexin (Loskutoff et al., 1983; Scott et al.,
1985; Sprengers and Kluft, 1987).

These proteins

inactivate both urokinase and tissue-type plasminogen
activators by forming covalent complexes with the active
site serine residues of the plasminogen activators
(Andreasen et al., 1986).

PAI-1 is an efficient inhibitor

of both urokinase and tissue plasminogen activators.

It

has been purified (van Mourik et al., 1984) and its cDNA
has been sequenced (Ny et al., 1986).

PAI-2, which reacts

more rapidly with urokinase than with tissue type
plasminogen activator, has also been purified (Astedt et
al., 1985) and the full length cDNA sequence has been
determined (Ye et al., 1987).

Future studies could
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transfect cloned PAI-1 and PAI-2 genes into metastatic
cells to evaluate their role in metastasis. It could be
predicted that PAI-1 and PAI-2 are metastatic suppresser
genes, in the same way as TIMP appears to be a metastatic
repressor protein (Khokha et al., 1988).

CHAPTER VI

SUMMARY
Metastasis is a process in which tumor cells detach
from their primary site(s), invade through the surrounding
tissue, and give rise to new lesions at sites distant from
the primary tumor(s).

Urokinase may have an important

role in tumor cell metastasis.

It has a proteolytic

enzyme activity which can promote degradation of
extracellular matrix and basement membrane.

In this

study, the role of urokinase in tumor cell metastasis was
examined by modifying the urokinase gene expression in
tumor cells.
A SV40 expression vector containing the human
preprourokinase gene (plasmid pSV2-uPA) was constructed
and cotransfected with a selection marker gene (pSV2-neo)
into murine Bl6-Fl melanoma cells of low metastatic
potential.

The expression of the human urokinase gene was

demonstrated by a filter immunoblot assay and an ELISA
using a monoclonal antibody to human urokinase.
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Southern
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blot hybridization analysis of the clone expressing the
highest level of human urokinase showed that the pSV2-uPA
plasmid was incorporated in approximately 150 copies.
These cells exhibited a 3 to 4-fold increase in secreted
urokinase activity.

The human urokinase synthesized by

the murine cells was found to be glycosylated.
Furthermore, it was shown that human urokinase does not
bind to the murine Bl6-Fl cell surface urokinase receptor
sites.

Thus the human urokinase is simply constitutively

synthesized and secreted by the transf ected murine
melanoma cells.
In the lung colonization assay which measures tumor
cell extravasation from the blood and subsequent pulmonary
tumor growth, the pSV2-uPA transfected cells showed a 4 to
18-fold increase in the ability to form lung tumors.

In

the spontaneous metastatic assay, which measures the full
metastatic process, the transfected cells showed an
absolute ability to metastasize (12 out of 12 mice), while
control cells showed a low ability to metastasize (only 2
out of 11 mice).

These results clearly show that an

increase in secreted urokinase activity promotes both lung
colonization and spontaneous metastasis.
In addition,

Bl6-Fl0 murine melanoma cells of high

metastatic ability were cotransfected with a 265 base pair
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cDNA containing the leader sequence of the human
preprourokinase gene in an antisense direction (plasmid
pSV2-ASuPA) and pSV2-neo.

Two of the antisense clones

secreted approximately 70% of the urokinase activity of
control cells.

Southern blot hybridization analysis

confirmed the incorporation of pSV2-ASuPA into the genomic
DNA.

In the lung colonization assay, the cells containing

antisense urokinase cDNA showed a 40 to 42% decrease in
the ability to form lung tumors.

These results support

the conclusion that urokinase is an important promoter of
the extravasation step in tumor cell metastasis.

It was

also observed that the majority of tumors from the control
mice (injected with pSV2-neo transfected cells) were
smaller than those of the experimental mice (injected with
pSV2-neo and pSV2-ASuPA transfected cells).

This result

indicates that inhibition of urokinase production may
decrease the metastatic potential and correspondingly
increase the tumorigenic potential of murine melanoma
cells.
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APPENDIX

APPENDIX
Prior to the use of pSV2 expression vector
pSV2-uPA (shown in Figure 3), the plasmid pRdzbuktt
(shown in Figure 1) which contains Rous sarcoma virus
(RSV) long terminal repeats (LTR) promoter was tested for
the preprourokinase gene expression.

The expression

vector containing RSV LTR promoter had been previously
used in a variety of murine cell lines other than Bl6 cell
lines (Gorman et al., 1982).

816-Fl cells were

cotransfected with pSV2-neo and pRdzbuktt, shocked with
glycerol, and grown in the presence of Geneticin as
described previously.

The DNAs were prepared from the

surviving cells of pSV2-neo and pRdzbuktt transfected or
pSV2-neo transfected cells.

To detect the pSV2-neo

incorporation, DNAs were digested with HindIII, or double
digested with HindIII/BamHI or HindIII/PstI, separated by
electrophoresis, transferred to nitrocellulose filter, and
probed with 32 P-labeled pSV2-neo fragment.

The digestion

of pSV2-neo with HindIII generates one single DNA band of
5729 base pairs and 32 P-labeled probe hybridizes with the

183

184
band.

The double digestion of pSV2-neo with HindIII and

~I

generates two DNA bands with base pairs of 3386 and

2346 and the probe hybridizes with the 2346 band.

The

double digestion of pSV2-neo with HindIII and PstI
generates five DNA bands with base pairs of 1883, 1430,
958, 923, and 535 and the probe hybridizes with the 1430
and 923 bands.

Figure 24 shows that the cells transfected

with pSV2-neo alone or cotransfected with pSV2-neo and
pRdzbuktt demonstrate the restriction endonuclease
digested bands identical to those of pSV2-neo plasmid.
To detect the pRdzbuktt incorporation, Southern
blot hybridization assay was performed using the 32 Plabeled sacI and HindIII fragment of pRdzbuktt as a probe.
However, in Figure 25, Southern blot hybridization assay
failed to show pRdzbuktt incorporation to the genomic DNA
of the transfected cells.

The production of plasminogen

activator by the pRdzbuktt transfected cells was
determined by the f luorogenic substrate assay and compared
to pSV2-neo transfected or untransfected cells.

As shown

in Table 15, the cells transfected with pRdzbuktt produced
same amounts of plasminogen activator as pSV2-neo
transfected or 816-Fl cells.

Taking Figure 25 and Table

15 together, the results show that the plasmid pRdzbuktt
was not incorporated into the genomic DNA of 816-Fl cells,
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Figure

2~.

Southern blot analysis of DNA isolated

from pSV2-neo and pRdzbuktt transf ected cells to
detect the pSV2-neo incorporation
DNAs were isolated from pSV2-neo transfected
or pRdzbuktt transfected Bl6-Fl cells.

The DNAs (10

ug) were cleaved with HindIII or double digested
with HindIII and BamHI or HindIII and PstI and
electrophoresed through 0.8% agarose gel.

A control

pSV2-neo plasmid preparation was similarly digested
with the same enzymes.

The DNAs were transferred to

nitrocellulose and probed with 32 P-labeled PvuII
fragment of pSV2-neo.

Lanes 1,2,3 contain DNA made

from the plasmid pSV2-neo, lanes 4,5,6 contain DNA
made from pSV2-neo transfected cells, and lanes
7,8,9 contain DNAs made from the pSV2-neo and
pRdzbuktt transfected cells.

DNAs in lanes 1,4,7

were digested with HindIII, DNAs in lanes 2,5,8 were
double digested with HindIII and BamHI, and DNAs in
lanes 3,6,9 were double digested with HindIII and
Pstr.
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Figure ?5.

Southern blot analysis of DNA isolated

from pSV2-neo and pRdzbuktt transf ected cells to
detect the pRdzbuktt incorporation
DNAs were isolated from pSV2-neo transf ected
or pRdzbuktt transfected Bl6-Fl cells.

The DNAs (10

ug) were cleaved with HindIII or double digested
with HindIII and SacI or HindIII and PstI and
electrophoresed through 0.8% agarose gel.

A control

pRdzbuktt plasmid preparation was similarly digested
with the same enzymes.

The DNAs were transferred to

nitrocellulose and probed with 32 P-labeled HindIIIPstI fragment of pRdzbuktt.

Lanes 1,2,3 contain DNA

made from the plasmid pRdzbuktt, lanes 4,5,6 contain
DNA made from pSV2-neo transfected cells, and lanes
7,8,9 contain DNAs made from the pSV2-neo and
pRdzbuktt transfected cells.

DNAs in lanes 1,4,7

were digested with HindIII, DNAs in lanes 2,5,8 were
double digested with HindIII and SacI, and DNAs in
lanes 3,6,9 were double digested with HindIII and
PstI.
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Table 15.

Quantification of plasminogen activator (PA)

production by B16-Fl, B16-F10, and transfected Bl6-Fl
cells with pSV2-neo or pRdzbuk.tt as determined by
f luorogenic substrate assaya

Cell

B16-Fl
B16-Fl (pSV2-neo)
B16-Fl (pRdzbuktt)
B16-Fl0

PA activityb
(Mean ± SD)

0.57
0.56
0.51
1.38

±
±
±
±

0 _09 c,d,e
0.13c
o.o7d
o.1oe

aB16-Fl, B16-F10, and B16-Fl transfected cells with pSV2neo or pRdzbuktt were incubated with fluorogenic substrate
for plasminogen activator, methoxysuccinyl-L-Gly-L-Gly-LArg-7-amino-4-methylcoumarin HCl. The ability of
plasminogen activator to release 7-amino-4-methylcoumarin
(AMC) from the substrate was measured.
bPlasminogen activator activity is expressed by the slope
of linear release of AMC under the assay conditions.
cNot significantly different (p = 0.92)
dNot significantly different (p = 0.31)
esignificantly different (p = 0.000)
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which subsequently failed to produce human urokinase.
Another attempt was made to express the human
preprourokinase gene by the plasmid, pCLH3AXBPV, which
contains bovine papilloma virus (BPV-1) with MT-1
(metallothreonine) promoter (Figure 4).

The insertion of

human preprourokinase gene into the pCLH3AXBPV is shown in
Figure 5 and the final plasmid structure, pCLH3AXBPV-uPA,
is shown in Figure 6.

The plasmid was similarly

transfected to Bl6-Fl cells and a fibrin overlay assay was
performed.

The fibrin overlay assay tests the transient

expression of urokinase gene prior to its incorporation to
the genomic DNA.

The optimum condition for the assay was

developed for Cl27 cells (mammary tumor cell line of an
RIII mouse obtained from American Tissue Culture Center,
No. CRL1616) transfected with pCLH3AXBPV-uPA as described
by Reddy et al. (1987).

The results in Figure 26

demonstrate the absence of plasminogen activator activity
in the fibrin agarose matrix which indicates the cells
transfected with plasmid pCLH3AXBPV-uPA did not produce
urokinase.

In contrast, Cl27 cells transfected with

pCLH3AXBPV-uPA gave positive results with respect to pSV2neo transfected controls (data not shown).
The efficiency of gene transfer under the control
of the viral regulatory sequence might have limitations
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Figure 26.

Fibrin overlay assay to detect the

transient expression of urokinase gene by the
transf ection of the plasmid pCLHJXBPV-uPA to B16-F1
cells
B16-Fl cells transfected with pCLH3AXBPV-uPA
were mixed with agarose in MEM supplemented with
10% heat inactivated FBS containing fibrinogen and
thrombin and incubated at 37°C overnight.

The

ability of plasmin, which was activated from
plasminogen by the urokinase, was detected by the
clearing zones of fibrin degradations on the
agarose matrix.

Plasminogen was supplied from the

FBS in the reaction mixture and f ibrinogen was
activated to fibrin by thrombin.

The cells

transfected with pCLH3AXBPV-uPA shows the absence
of clearing zones which indicate that the cells did
not produce urokinase (top).

A control which contained

several drops of urokinase solution showed clearing
circles of fibrin degradation (bottom).
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which affect its application to certain cell lines.

For

example, it has been suggested that the flanking long
terminal repeats (LTRs) as well as BPV vectors may
interfere with transcriptional regulation of the inserted
foreign gene sequences that could lead to a lack of
expression in certain cell lines (Howard, 1983).
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